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ABSTRACT 
Locating at the outer surface of cells, glycans and their glycoconjugates play multitude of 
roles in biological processes. Among these, protein O-GlcNAcylation is involved in a variety of 
age related diseases, such as Alzheimer’s disease, diabetes, and cancer development. O-GlcNAc 
cycling is catalyzed by only two enzymes: O-GlcNAc transferase (OGT) and O-GlcNAcase 
(OGA), raising key questions regarding the regulation and selectivity of these enzymes. In project 
one, we synthesized a series of glycopeptide substrates with various GlcNAc derivatives to study 
the specificity of human OGA. Several sugar moieties were discovered to be resistant to OGA 
hydrolysis which had the potential to be used as O-GlcNAcylation probes through metabolic 
glycan labeling (MGL).  
Installation of an antibody-recruiting moiety on the surface of disease-relevant cells can 
lead to the selective destruction of targets by the immune system. Herein, in project two, taking 
advantage of MGL strategy, we synthesized the folic acid-azidosugar conjugate and described the 
development of a new strategy to selectively deliver azidosugar and introduce L-rhamnose 
antigens via click chemistry onto cancer cell surface. The immune system can be further activated 
by the installed antigens to clear out cancer cells. Such an approach can be an alternative and 
potential strategy to traditional chemotherapeutics in cancer therapy and possibly other diseases.  
Carbohydrate-protein interactions are essential for body function, but implicated to capture 
and identify. In project three, we aim to develop a novel method to lock carbohydrate-protein 
interactions in a covalent form. Expanding the genetic code to incorporate crosslinkers into 
proteins enables us capture and identify unknown glycoproteins, manipulate carbohydrate-protein 
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1   PRODUCTION OF GLYCOPEPTIDE DERIVATIVES FOR EXPLORING 
SUBSTRATE SPECIFICITY OF HUMAN OGA TOWARDS SUGAR MOIETY 
1.1   Introduction  
1.1.1  General introduction to carbohydrates 
Carbohydrates have the general composition of Cx(H2O)n. Carbohydrates contain aldehyde 
or ketone group and are named aldose or ketose respectively. Monosaccharides are the simple 
sugars with multiple OH groups, and can be a triose, tetrose, pentose or hexose based on number 
of carbons.1 The presentation of a monosaccharide includes two forms: Fisher projection and 
Haworth projection which is cyclic form. The cyclic five- and six-membered rings are the common 
form due to the chemical stability, although monosaccharides exist as an equilibrium of acyclic 
and cyclic forms in solution.2 The numbering of carbon atoms are determined as following in 
Fisher projection: the aldehyde carbon is C-1 and the carbonyl carbon in ketose is C-2. The 
numbering rules in Haworth projection are labeled as Fig 1.1. 
 
Figure 1.1 Numbering rules and the conversion from Fischer to Haworth projection. 
The conversion from Fisher projection to Haworth projection and the numbering of each 
carbon.  
 
Hundreds of distinct monosaccharides are discovered in nature, however, only a few of 






























for the representation of glycans has been developed for efficient communications in science.3 
Monosaccharide was presented by simple shapes, such as round, square, triangle, diamond, five-
pointed star and so on, with different standard colors including yellow, green, blue, red, orange 
and purple. The general information including the systematic name, abbreviation, graphic 
nomenclature and standard color of the common monosaccharedes involved in this thesis was 
showed in Fig 1.2. The full list of universal symbol nomenclature for each monosaccharide was 
available on the website.4 
 














Standard colors: R, G, B
Fuc
Neu5Ac Neu5Gc
Yellow    
Blue       
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Red        
Orange   











N-Acetylneuraminic acidNeu5Ac 5-Acetamido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosonic acid




Sialic acidSia Sialic acid residue of unspecified type
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1.1.2  Glycosylation precursor: sugar nucleotides 
 
Figure 1.3 Enzymatic synthesis of sugar nucleotides.  
(A) The chemical structures of common used nucleoside triphosphates donors: UTP, GTP 
and CTP. (B) Scheme to enzymatically synthesize the sugar nucleotides. The monosaccharide is 
phosphorylated by sugar-1-kinase to get sugar-1-phosphate, which is then activated to sugar 
nucleotide by sugar nucleotide pyrophosphorylase in the presence of UTP. 
 
In glycan synthesis, monosaccharides need to be activated to a high-energy form in order 
to be conjugated with proteins, lipids or oligosaccharides. This process requires the high-energy 
donor, nucleoside triphosphates, such as UTP, GTP or CTP (Fig 1.3 A). Set GlcNA as example, 
two steps are included: first, GlcNAc was activated to GlcNAc-1-phosphate via sugar-1-kinase; 
second, GlcNAc-1-phosphate was then activated to UDP-GlcNAc with UTP as high-energy donor 
via sugar nucleotide pyrophosphorylase (Fig 1.3 B). The most common sugar nucleotides in 
vertebrates are listed (Fig 1.4). Glucose (Glc), Galactose (Gal), GlcNAc, GalNAc, GlcA, and 
Xylose (Xyl) used UTP as high-energy donor, while Fuc (fucose) and Man (Mannose) used GTP 
























































































Figure 1.4 List of common sugar nucleotide structures in vertebrates. 
 
1.1.3  Major vertebrate glycan classes and their function 
All the cells are coated by a dense of complex sugars (monosaccharides or 
oligosaccharides, all referred to as glycans) in nature.1 These glycans are covalently attached to 
proteins or lipids, forming various glycoconjugates, such as glycoproteins and glycolipids. 
Locating at the outer surface of cells or macromolecules, glycans can mediate cellular events in 
cell signaling transduction, cell-cell and cell-matrix adheren.5 For example, the interactions of 
selectins with cell-surface glycoconjugates mediate tethering and rolling adhesion of leukocytes 
and platelets on vascular surfaces.6 Another example is CD22 interactions. CD22 interacts with 
glycan ligands on B cell surface and functions as a negative regulator of signaling.7-8 Three major 
classes of eukaryotes glycans exist: glycoproteins, glycolipids and proteoglycans. Glycoproteins 
include N-glycan, O-glycan, O-GlcNAc and GPI-anchored glycoproteins. Glycosphingolipids are 
the typical glycolipids attached on ceramide. Proteoglycans are glycosaminoglycans (GAG’s) 













































































































































Glycans are tissue specific and closely related to disease development. For  example, sialyl 
LewisX [Siaα2,3-Galβ1,4-(Fucα1,3-)GlcNAc] was shown to be overexpressed on cancer  cell 
sur face,9  also par ticipate in the mediation of leukocyte recruitment and human sperm 
binding dur ing fer tilization.10-11 Many smart human pathogens coated themselves with a high 
density of sialic acids which could be recognized by human siglecs receptor on immune cell 
surface.12 That suggested that pathogens had the machinery to mimic glycans of human cell surface 
in order to downregulate the innate immune response and increase the entry and survival in human 
host.5 Moreover , aberrant protein O-GlcNAcylation plays a critical role in a variety of age related 
diseases, such as Alzheimer’s disease, diabetes, and cancer development.13-14 O-GlcNAcylation 
will also be the focus of this chapter and will be expanded in details below. 
1.1.4  O-GlcNAcylation 
Protein glycosylation is an important protein post-translational modification in various 
organisms and is critical for a wide range of biological processes. Defective or aberrant 
glycosylation can lead to serious cellular dysfunction or diseases in humans.15 O-GlcNAcylation 
(Fig 1.5) is a single N-acetylglucosamine β-linked to the serine or threonine residues of some 
nucleic and cytoplasmic proteins, and is essential for multiple cellular signaling cascades, 
including gene transcription, protein translation, cell cycle, and nutrient sensing.16-18 O-
GlcNAcylation is a dynamic reversible process, the addition and removal of GlcNAc residues from 
a protein is regulated by only two enzymes. Uridine diphosphate-N-acetyl-D-glucosamine: 
polypeptidyl transferase (OGT) is responsible for transferring a single GlcNAc from uridine 
diphosphate-α-N-acetyl-D-glucosamine (UDP-GlcNAc) to proteins. The other enzyme is O-
GlcNAcase (OGA) which removes GlcNAc from glycoproteins. 
6 
 
Figure 1.5 Chemical linkage of O-GlcNAc modification. 
 
By affecting the stability, activity, or interactions of key signaling proteins, O-
GlcNAcylation plays a vital role in disease development. 19-21 For example, Tau oligomerization 
mainly contributes to neurons death leading to Alzheimer’s disease. Researchers found that 
increasing O-GlcNAc on tau would inhibit tau aggregates and decrease neuron cell death in vivo.21 
Researchers have also shown that OGA inhibitors could increase O-GlcNAcylation and slow 
neurodegeneration without apparent adverse effects in mouse model.22 Those studies exemplified 
the utility of OGA as a potential therapeutic target for Alzheimer’s disease and other neuron related 
diseases. Another example is the role of O-GlcNAcylation in diabetes. Increasing levels of O-
GlcNAcylation on protein NeuroD1 leaded to the translocation to nucleus, and sequentially 
increased insulin levels.23 O-GlcNAcylation is also involved in the cancer development. Studies 
on primary cancer tissue and patients have suggested that increased O-GlcNAc correlates with 
increased cancer progression and metastasis in general.24 Because of the importance of O-GlcNAc 
and its crucial roles in biological signaling, aging-related diseases and even cancer progression, 
the enzymes controlling O-GlcNAcylation levels are considered as valuable and potential 
therapeutic targets.   
1.1.5  O-GlcNAc transferase (OGT) 
O-GlcNAcylation is a dynamic reversible process, the addition and removal of GlcNAc 














glucosamine: polypeptidyl transferase (OGT) is responsible for transferring a single GlcNAc from 
uridine diphosphate-α-N-acetyl-D-glucosamine (UDP-GlcNAc) to proteins. Human OGT 
generally contains N-terminal tetratricopeptide repeat (TPR) units and the catalytic region which 
comprising three domains: the amino (N)-terminal domain (N-Cat), the intervening domain (Int-
D) and the carboxy (C)-terminal domain (C-Cat). It has three isoforms with different TPR units: 
short OGT (sOGT), mitochondrial OGT (mOGT) and nucleocytoplasmic OGT (ncOGT).25 
 
Figure 1.6 OGT crystal structures (PDB 3PE4). 
 (A) Cartoon presentation of OGT domains. The C-catalytic domain was shown in red, 
N-catalytic domain was shown in blue, the intervening domain was shown in green, TPR region 
was shown in grey. (B) close up view of OGT complexed with UDP and peptide substrates.  
 
The crystal structure of hOGT (consisting 4.5 TPR units) complexed with UDP and a 
peptide substrate (YPGGSTPVSSANMM, the underlined serine was glycosylated) has been 
solved in 2011 (Fig 1.6 A).26 The hydroxyl of serine was shown to point into the binding pocket 
of hOGT, having interactions with residue H498 (Fig 1.6 B). Based on the structural analysis and 
other kinetic data in that paper, researchers proposed the general mechanism for human OGT. 
H498 is essential for human OGT activity and act as the catalytic base to accept proton from serine 
of substrate peptide; and the other residue, K842 has been proven to interact with the 







substrate specificity has also been widely investigated. Among the 26 UDP-sugar derivatives, 4 
(UDP-GlcNPr, UDP-6-deoxy-GlcNAc, UDP-4-deoxy-GlcNAc and UDP-6-deoxy-GalNAc) were 
reported to highly glycosylate peptides via sOGT-catalyzed glycosylation.28 Peptide sequence is 
vital for O-GlcNAcylation, especially -2, -1 and +2 positions, and uncharged amino acids are 
preferred and show high reactivity.29  
1.1.6  O-GlcNAcase (OGA): structure and substrate promiscuity 
 
Figure 1.7 Human OGA structures (PDB 5TKE). 
 (A) The catalytic domain was shown in magenta, two stalk domain was separated and 
colored in cyan, and another HAT domain was labeled as yellow. Cartoon presentation of OGA, 
side view (B), top view (C). Catalytic domain of OGA-α is shown in magenta, stalk domain of 
OGA-α is shown in cyan, and OGA-β is shown in grey. 
 
The other enzyme controlling O-GlcNAcylation is OGA which removes GlcNAc residue 
from glycopeptide. OGA inhibitors have been of great interest as tools to increase O-
GlcNAcylation levels, thus to modulate and study the O-GlcNAc biology. O-(2-Acetamido-2-
deoxy-D-glucopyranosylidene)-amino-N-phenylcarbamate (PUGNAc, Ki=46 nM) was the first 
1 60 366 395 553 706 916 aa
A
CB
catalytic domain Stalk domain HAT domain
9 
extensively used OGA inhibitor in a range of cellular processes.30 However, it was also a powerful 
inhibitor of human lysosomal hexosaminidases A/B (Hex A/B).31 A wide range of OGA inhibitors 
have been identified following, such as 6-acetamido-6-deoxy-castanospermine (6-Ac-Cas)  
(Ki=300 nM), 1,2-dideoxy-20-methyl-α-D-glucopyranoso-[2,1-d]-D-20-thiazoline (NAG-
thiazoline) (Ki =70 nM), and Thiamet-G  (Ki=21 nM, 37,000-fold selectivity over Hex A/B ).32-34 
Researchers have shown that the OGA inhibitor, Thiamet-G, could increase O-GlcNAcylation and 
slow neurodegeneration without apparent adverse effects in mouse model.22 These studies have 
exemplified the utility of OGA inhibitors as a potential therapeutic target for Alzheimer’s disease 
and other related diseases. 
 
Figure 1.8 Crystal structure of human OGA complexed with p53 glycopeptide (PDB 
5UN8). 
 (A) Interactions between GlcNAc on glycopeptide and residues on catalytic domains of 
OGA. (B) Interactions between p53 peptide and catalytic and stalk domains of OGA. 
 
Due to the important role of O-GlcNAcylation and OGA inhibitors, the structural basis and 
the substrate promiscuity of OGA has been of great interest for the development of therapeutic 
reagents targeting OGA. Human OGA consists catalytic domain (residues 60–366), stalk domain 


















have solved the structure of hOGA and revealed that hOGA existed as an unusual arm-in-arm 
homodimer (Fig 1.7 B and C).35-37 Jiang group solved the structure of OGA complexed with an O-
GlcNAcylated peptide substrate (Ac-QLWVDS(O-GlcNAc)TPPPG).35 As Figure 1.8 shown, 
numbers of hydrogen bonding anchored the GlcNAc residue towards OGA binding pocket. Several 
key amino acids on OGA have been marked including D285, N311, K98, D174 and N280. D285 
interacts with the hydroxyl group on C6 and C5; N311 interacts with hydroxyl on C5; K98 had 
hydrogen bonding with hydroxyl on C3; D174 interacts with nitrogen on C2 and N280 interacts 
with carbonyl on C2. Furthermore, the hydrophobic residues, such as Y69, Y219, F223, V254 on 
catalytic domain, and M622, F625, W645, M653, W679 on the stalk domain from the sister OGA 
monomer, formed a hydrophobic pocket for peptide binding which were conserved in most 
eukaryotes (Fig 1.8 B). So far, the structural basis of OGA has been uncovered and fully studies. 
However, partly because of the difficulties in obtaining glycopeptides with modified GlcNAc 
residues, the substrate promiscuity of OGA towards GlcNAc-recognition was still unclear. In this 
project, glycopeptides containing different GlcNAc derivatives were successfully synthesized and 
purified to investigate the substrate promiscuity of hOGA. The result will provide guidelines for 
the design of O-GlcNAcylation probes to better understand its biological roles in living system. 
1.2   Objectives of the project 
In this study, a set of glycopeptides with modifications on the GlcNAc residue were 
prepared in a recombinant full-length human OGT-catalyzed reaction using chemoenzymatically 
synthesized UDP-GlcNAc derivatives. The resulting glycopeptides were used to evaluate the 
substrate promiscuity of hOGA towards the sugar moiety. We anticipate this study will provide 
insight into the exploration of probes for O-GlcNAc modification as well as better understanding 
the roles of O-GlcNAc in cellular physiology.  
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1.3   Results and discussion  
1.3.1  Synthesis of GlcNAc derivatives 
4-deoxy-GlcNAc and GlcNAz were synthesized according to our previous report38. The 
other three new compounds, GlcNPr, 4-OMe-GlcNAc, and 6-deoxy-GlcNAc, were synthesized 
for the first time in this study (Fig 1.9). GlcNPr was generated in the presence of propionyl chloride 
and pyridine after global deprotection. A convergent route was designed to synthesize 6-deoxy-
GlcNAc and 4-OMe-GlcNAc; GlcNAc as the starting material was first protected with benzylidine 
and then subjected to 1,3-acetylation to afford intermediate 5. Selective deprotection of 
benzylidine was carried out in the presence of NBS and calcium sulfate to afford 6. The desired 
target compound 8 was obtained after reduction of the bromide and full deacetylation. For 4-OMe-
GlcNAc, bezylidine in 5 was removed and selective acetylation of the 6-OH freed the 4-OH, which 














a.  Propionyl   chloride,   Pyridine,  CH2Cl2,  82%;;  b.  MeONa,  MeOH,  84%  for  3,  83%  for  8;;  c.  i)  PhCHO,  ZnCl2,  92%;;  ii)  Ac2O,  Pyridine,   85%;;  























































Figure 1.9 Synthetic methods of compounds: GlcNPr, 4-OMe-GlcNAc, and 6-deoxy-
GlcNAc. 
 
1.3.2  Protein expression and purification 
According to previous studies, we expressed Bifidobacterium infantis N-acetylhexosamine 
12 
1-kinase ATCC#15697 (BiNahK), human UDP-N-acetylgalactosamine pyrophosphorylase 
(hAGX1), human OGT (ncOGT), and human OGA (hOGA) in Escherichia coli (E. coli)39-42. 
Enzymes were expressed by induction with 1 mM of isopropyl 1-thio-β-D-galactopyranoside 
(IPTG) followed by incubation at 16 °C for 24 h with vigorous shaking (200 rpm). After 
purification, 15 mg ncOGT, 20 mg hOGA, 40 mg BiNahK, and 20 mg hAGX1 were obtained 
respectively from 1 L of E. coli culture. Enzymes was confirmed through SDS-PAGE. 
1.3.3  Production of UDP-GlcNAc derivatives 
Table 1 Synthesis of UDP- GlcNAc derivatives using BiNahK and hAGX1. 
 
 
UDP-GlcNAc was purchased from Carbosynth (San Diego, CA, USA). UDP-GlcNPh, 
UDP-GlcNGc, UDP-GlcNTFA, and UDP-6-N3-GlcNAc were gifts from Professor Xi Chen (UC 
Davis, USA) and synthesized as reported previously43. Other sugar nucleotides were obtained 
through a chemoenzymatic strategy by chemical synthesis of GlcNAc derivatives, which were 
used as the substrates in a one-pot two-enzyme system containing BiNahK and hAGX1. The 































































































































































characterized by capillary electrophoresis (CE) and matrix-assisted laser desorption/ionization 
(MALDI) mass spectrometry (See Appendex A).  
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Figure 1.10 Peptide structure used in this project and its characterization. 
 (A) The structure of peptide used in this study; (B) the MALDI identification of peptide; 
(C) the peptide purity was confirmed by HPLC. HPLC condition: elute by 5 % -35 % acetonitrile 
with 0.1 % TFA for 30 min at 2.5 mL/ min flow rate. 
 
The peptide substrate (YAVVPVSK) was synthesized based on the Fmoc-strategy using a 
Liberty Blue Peptide Synthesizer and purified by high-performance liquid chromatography 
14 
(HPLC) (Fig 1.10).10 A set of glycopeptides carrying modifications on the GlcNAc residue were 
subsequently prepared in a recombinant full-length hOGT-catalyzed reaction using 
chemoenzymatically synthesized UDP-GlcNAc derivatives. The hOGT enzyme reactions were 
carried out at 37 °C for 2 h in a volume of 100 µL containing 1 mM peptide, 3 mM UDP-GlcNAc 
analogs, and 50 µg ncOGT in buffer (50 mM Tris-HCl, pH 7.5, 10 mM Mg2+). The reaction was 
boiled, and the products were subjected to HPLC purification and yield quantification. Each peak 
was collected and identified through MALDI.  
















































































































































































































































































































































By utilizing this method, ten glycopeptide derivatives (five glycopeptides with C2-
modified GlcNAc, three glycopeptides with C4-modified GlcNAc, and two glycopeptides with 
C6-modified GlcNAc) were produced, purified by HPLC, and characterized by MALDI (See 
Appendex B). The OGT reaction efficiency was calculated as the glycopeptide yield (Y%). The 
yield was calculated with the formula Y = S1/(S1+S2), where S1 and S2 are the integrated areas 
of the glycopeptide and peptide peaks, respectively. All UDP-GlcNAc derivatives were good 
substrates for hOGT except for UDP-6-N3-GlcNAc, which resulted in only 23.8% yield in vitro 
(Table 2). Notably, hOGT was the full-length isoform with 13.5 tetratricopeptide repeats (TPRs), 
which showed higher activity than sOGT (short OGT with 2.5 TPRs). For example, when sOGT 
was used, six UDP-GlcNAc derivatives (UDP-GlcNGc, UDP-GlcNAz, UDP-GlcNTFA, UDP-
GlcNPh, UDP-6-N3-GlcNAc, and UDP-GalNAc) used as the substrates produced less than 1% 
yield.28 In comparison, over 49% yield was obtained when full-length hOGT was used. The crystal 
structures of the N-terminal domain of full-length hOGT containing the first 11.5 TPRs showed 
that the conserved asparagine residues in the TPR domain directly contacted the substrates, 
supporting the role of the TRP domains in initial recognition and substrate specificity 
determination.44 In summary, in addition to preparing glycopeptides, we found that full-length 
hOGT is a more efficient catalyst than the previously reported sOGT.  
1.3.5  OGA substrate specificity assay 
The glycopeptide peaks from OGT reactions were collected and lyophilized for the hOGA 
substrate specificity assay. The hOGA reaction was conducted overnight in a volume of 100 µL 
containing the glycopeptides, MgCl2 (20 mM), Tris–HCl (200 mM), and recombinant hOGA (0.1 
mg). The reaction mixture was boiled and centrifuged before HPLC separation. Each peak was 
collected and characterized by MALDI. The hOGA hydrolysis yield (Y %) was calculated using 
16 
the formula Y = S2/(S1+S2), where S1 and S2 are the integrated areas of the glycopeptide and 
peptide peaks, respectively. The GlcNAz-peptide and 6-N3-GlcNAc-peptide were well-tolerated 
by hOGA, and other glycopeptide derivatives significantly decreased the efficiency of hOGA, 
showing less than 10% hydrolysis yield (Table 3). The results revealed that hOGA had a relatively 
strict recognition for the sugar moiety in the glycopeptides, thus exhibiting limited activities for 
glycopeptide derivatives with C2, C4, and C6 modifications on GlcNAc. 























































































































































































































































































































































1.4   Materials and general methods  
1.4.1  Compound chemical synthesis procedures 
Synthesis of GlcNPr  
1,3,4,6-Tetraactyl Glucosamine hydrochloride (200 mg, 0.52 mmol) was dissolved in 10 
mL anhydrous CH2Cl2, pyridine (82 µL, 1.04 mmol) was added at 0 ℃, 10 mins later, propionyl 
chloride (90 µL, 1.04 mmol) was added dropwise and the mixture was allowed to warm to room 
temperature gradually and continuously reacted at this temperature overnight. Added 1 mL MeOH 
to quench the reaction and the mixture was diluted with 30 mL CH2Cl2, washed with 10 mL 1 M 
HCl and saturated sodium bicarbonate in sequence, the combined the organic layer was dried over 
anhydrous Na2SO4. The solvent was dried by vacuum to furnish the crude product which was 
purified by flashing silica gel column chromatography. The desired product was obtained as white 
solid 2 (172 mg, 82 %). 1H NMR (400 MHz, CDCl3) δ5.82 (dd, J = 13.6, 9.9 Hz, 1H), 5.69 (d, J 
= 8.8 Hz, 1H), 5.19 - 5.08 (m, 2H), 4.34 – 4.22 (m, 2H), 4.11 (dd, J = 12.5, 2.0 Hz, 1H), 3.81 (ddd, 
J = 9.5, 4.6, 2.2 Hz, 1H), 2.15 – 2.06 (m, 8H), 2.02 – 2.01 (m, 6H), 1.07 (dd, J = 8.0, 7.2 Hz, 3H); 
13C NMR (100 MHz, CDCl3) δ 173.97, 171.25, 170.70, 169.56, 169.30, 92.64, 72.91, 72.65, 67.87, 
61.75, 52.75, 29.80, 20.85, 20.71, 20.63, 20.57, 9.85. 
The intermediate 2 (172 mg) was dissolved in 10 mL dry MeOH and catalytic MeONa was 
added to adjust the pH 9 ~10, the reaction was stirred at room temperature for 5 h. After that, 
Dowex acid resin was added to make the mixture neutral. Filtrated to remove the resin and collect 
the filtration to afford the residue. After flashing the silica gel column to afford the desired product 
as colorless oil 3 (84.3 mg, 84%). 1H NMR (400 MHz, CD3OD) δ 5.03 (d, J = 3.4 Hz, 1H), 3.79 – 
3.71 (m, 3H), 3.66 – 3.61 (m, 2H), 3.35 – 3.27 (m, 1H), 2.20 (q, J = 15.2, 7.7 Hz, 2H), 1.06 (t, J = 
18 
7.6 Hz, 3H); 13C NMR (100 MHz, CD3OD) δ 177.43, 92.57, 73.08, 72.62, 72.50, 62.81, 55.78, 
30.07, 10.40. 
Synthesis of 6-deoxy GlcNAc  
Compound 5: N-Acetyl-Glucosamine (8 g, 36.1 mmol) and ZnCl2 (5 g, 36.6 mmol) were 
dissolved in 20 mL dry PhCHO under the protection of N2, the mixture was stirred overnight at 
room temperature. The white solid was washed with water (2 × 100 mL) and hexane (2 × 100 mL) 
to afford the pure product as white solid (10.2 g, 92 %). 
The intermediate (10 g, 32.3 mmol) was dissolved in 100 mL dry pyridine at 0 ℃, and 
Acetyl anhydride (9.2 mL, 97 mmol) was added dropwise. The mixture was allowed to warm to 
room temperature and stirred overnight at this temperature. Removal of the solvent by vacuum 
pump and then the residue was diluted with CH2Cl2 300 mL, the organic layer was washed with 1 
M HCl (100 mL), saturated NaHCO3 (100 mL) and brine (100 mL) sequentially, the organic layer 
was combined and dried over anhydrous Na2SO4. The solvent was removed to provide the crude 
product which was purified by flashing silica gel column chromatography to yield the pure product 
as white solid 5 (10.8 g, 85 %) 
Compound 6: To the solution of 5 (600 mg, 1.52 mmol) in dry CCl4, N-Bromosuccinimide 
(407 mg, 2.29 mmol) and Calcium carbonate (167 mg, 1.67 mmol) were added. The mixture was 
refluxed for 4h and then cooled to the room temperature. The mixture was diluted with DCM 100 
mL and washed with 1 M HCl (30 mL), saturated NaHCO3 (30 mL) and brine (30 mL) 
sequentially. The combined organic layer was dried over anhydrous Na2SO4 and the solvent was 
removed under reduced pressure. The crude product was purified by flash chromatography, giving 
a colorless oil 6 (538 mg, 75%). 1H NMR (400 MHz, CDCl3) δ 8.00 (dd, J = 8.3, 1.2 Hz, 1H), 7.63 
– 7.59 (m, 1H), 7.48 – 7.44 (m, 1H), 6.24 (d, J = 3.7 Hz, 1H), 5.64 (d, J = 8.3 Hz, 1H), 5.44 – 5.36 
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(m, 2H), 4.56 (ddd, J = 10.8, 9.1, 3.7 Hz, 1H), 4.14 (ddd, J = 9.0, 6.0, 2.6 Hz, 1H), 3.52 – 3.39 (m, 
2H), 2.23 (s, 1H), 1.95 (s, 1H), 1.94 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 171.49, 169.71, 
168.32, 164.67, 133.62, 129.60, 128.44, 90.32, 71.00, 70.39, 70.16, 50.85, 30.48, 22.81, 20.70, 
20.39. 
Compound 7: Compound 6 (250 mg, 0.53 mmol) and azodiisobutyronitrile (AIBN, 43.5 
mg, 0.26 mmol) were dissolved in dry Toluene. Bu3SnH (0.2 mL, 0.79 mmol) was added to the 
solution and the mixture was heated to 80 ℃ with argon protection. The reaction mixture was 
stirred for 5 h at this temperature. TLC analysis indicated that the starting material was consumed 
completely. The solvent was evaporated under reduced pressure and the residue was purified using 
flash chromatography to provide the desired product as white solid 7 (175 mg, 84 %). 1H NMR 
(400 MHz, CDCl3) δ 7.99 – 7.96 (m, 2H), 7.57 (t, J = 7.4 Hz, 1H), 7.446 – 7.41 (m, 2H), 6.14 (d, 
J = 3.7 Hz, 1H), 5.72 (d, J = 8.9 Hz, 1H), 5.38 – 5.32 (m, 1H), 5.15 (t, J = 9.7 Hz, 1H), 4.50 (ddd, 
J = 11.1, 9.1, 3.7 Hz, 1H), 4.05 – 3.98 (m, 1H), 2.19 (s, 3H), 1.92 (s, 3H), 1.90 (s, 3H), 1.22 (d, J 
= 6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.84, 170.06, 169.01, 165.23, 133.63, 129.77, 
128.63, 90.86, 73.30, 70.64, 68.15, 51.45, 23.08, 21.05, 20.70, 17.53. 
Compound 8: Compound 7 (100 mg, 0.25 mmol) was dissolved in dry methanol and 
catalytic amount MeONa was added to adjust the pH 9~10. The reaction mixture was stirred at 
room temperature for 4 h. Dowex acid resin was added to neutralize the mixture until the pH to 
6~7. The solvent was evaporated in vacuo and the crude product was purified by flash silica gel 
chromatography to provide the pure product as colorless oil 8 (43.3 mg, 83%). 1H NMR (400 MHz, 
CD3OD) δ 4.97 (d, J = 3.5 Hz, 1H), 4.51 (d, J = 8.4 Hz, 0.74H), 3.83 – 3.77 (m, 1.79 H), 3.62 – 
3.53 (m, 1.76 H), 3.37 – 3.34 (m, 0.75 H), 2.98 (td, J = 9.1, 4.0 Hz, 1.54 H), 1.94 (s, 4.64 H), 1.23 
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(d, J = 6.2 Hz, 2.1 H), 1.17 (d, J = 6.3 Hz, 3H); 13C NMR (100 MHz, CD3OD) δ 174.30, 173.72, 
96.76, 92.41, 78.15, 77.47, 75.72, 73.23, 72.47, 68.25, 58.86, 56.11, 22.95, 22.68, 18.23, 18.18. 
Synthesis of 4-OMe-GlcNAc  
Compound 9: The intermediate 5 (1.0 g, 2.5 mmol) and p-toluenesulfonic acid (43 mg, 
0.25 mmol) were dissolved in dry DCM 50 mL, and ethanethiol (0.73 mL, 10.1 mmol) was added 
to the solution at room temperature. The reaction mixture was stirred at this temperature for 4h. 
The solvent was evaporated under reduced pressure. The crude product was purified with flash 
chromatography to furnish the desired product as white solid (572 mg. 75 %). The whole 
intermediate (572 mg, 1.9 mmol) and pyridine (2.3 mL, 2.8 mmol) were suspended in dry DCM 
20 mL at ice-bath, acetyl chloride (0.15 mL, 2.1 mmol) was added dropwise in 10 min. After that 
the ice-bath was removed to allow the mixture warm to room temperature. The mixture continually 
reacted for another 6h. Methanol (0.5 mL) was added to quench the excess acetyl chloride and the 
solvents were evaporated under reduced pressure. The crude product was purified using flash 
chromatography to provide the desired product as white solid 9 (568 mg, 86 %). 1H NMR (400 
MHz, CDCl3) δ 6.14 (d, J = 3.6 Hz, 1H), 5.91 (d, J = 8.9 Hz, 1H), 5.09 (dd, J = 10.9, 9.4 Hz, 1H), 
4.51 (dd, J = 12.4, 3.6 Hz, 1H), 4.32 (ddd, J = 11.1, 9.0, 3.6 Hz, 1H), 4.20 (dd, J = 12.3, 1.9 Hz, 
1H), 3.84 (d, J = 9.7 Hz, 1H), 3.66 – 3.60 (m, 1H), 3.54 (d, J = 5.4 Hz, 1H), 2.16 (s, 3H), 2.11 (s, 
3H), 2.10 (s, 2H), 1.91 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 172.18, 171.94, 170.65, 169.22, 
90.91, 72.65, 72.17, 67.84, 62.61, 51.24, 23.01, 21.01, 20.97, 20.86. 
Compound 10: To the solution of 9 (200 mg, 0.57 mmol) and silver oxide (1.32 g, 5.7 
mmol) were dissolved in dry DCM 20 mL, the flask was protected with aluminized paper, and 
methyl iodide (0.36 mL, 5.7 mmol) was added to the solution at ice-bath. The ice-bath was 
removed and gradually warm to room temperature and reacted at ambient temperature overnight. 
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The reaction mixture was filtrated and the filtration was collected and evaporated under reduced 
pressure. The crude product was purified using flash chromatography to afford the pure product 
as white solid 10 (161 mg, 78 %). 1H NMR (400 MHz, CDCl3) δ 6.07 (d, J = 3.6 Hz, 1H), 5.73 
(d, J = 9.1 Hz, 1H), 5.16 (dd, J = 10.9, 9.2 Hz, 1H), 4.37 – 4.31 (m, 1H), 4.26 – 4.24 (m, 1H), 3.86 
– 3.75 (m, 1H), 3.44 (s, 3H), 2.13 (s, 2H), 2.09 (s, 3H), 2.08 (s, 3H), 1.90 (s, 4H); 13C NMR (100 
MHz, CDCl3) δ 171.65, 170.66, 170.18, 168.89, 90.84, 76.96, 73.22, 70.90, 62.35, 60.80, 51.26, 
23.03, 21.01, 20.95, 20.80. 
Compound 11: Compound 10 (161 mg, 0.44 mmol) was dissolved in dry methanol and 
catalytic amount MeONa was used to adjust the pH value to 9~10. The reaction mixture was stirred 
at room temperature overnight. Dowex acid resin was added to neutralize the mixture until the pH 
to 6~7. The solvent was evaporated in vacuo and the crude product was purified by flash silica gel 
chromatography to provide the pure product as colorless oil 11 (88 mg, 84 %). 1H NMR (400 MHz, 
D2O) δ 5.19 (d, J = 3.2 Hz, 1H), 3.89 – 3.81 (m, 5H), 3.59 (s, 3H), 3.57 – 3.55 (m, 1H), 3.29 (t, J 
= 9.0 Hz, 1H), 2.06 (s, 4H); 13C NMR (100 MHz, D2O) δ 174.49, 90.69, 79.76, 70.60, 70.43, 60.34, 
60.17, 54.14, 21.88. 
Synthesis of 4-Deoxy-GlcNAz and GlcNAz 
The synthesis of 4-Deoxy-GlcNAz and GlcNAz were described as previously published 
paper.38 
1.4.2  Synthesis of sugar nucleotides with BiNahK, and hAGX1  
The synthesis of sugar nucleotides were described as previously published paper.45 In brief, 
the reactions were carried out in the system containing a monosaccharide (30 mM), UTP (30 mM), 
ATP (30 mM), MgCl2 (20 mM)  and Tris–HCl (200 mM), pH 8.0, recombinat NahK (0.5 mg), 
recombinant AGX1 (0.5 mg). After incubation at 37 °C for 24 h, UDP sugar products were purified 
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with Bio-Gel P-2 column, and further characterized by mass spectrometry and capillary 
electrophoresis. 
1.4.3  Synthesis of peptide  
Automated peptide synthesis was performed on Liberty Blue Peptide Synthesizer through 
Fmoc-strategy. Peptides were synthesized on Wang resins which were purchased from 
Novabiochem, and HBTU was used as activator, DIEPA as base. Double coupling was performed 
with microwave under 50 °C for 10 min. The deblock mixture was 20 % piperidine in DMF. 
Cocktail of TFA/TIS/Dodt/H2O (92.5: 2.5: 2.5: 2.5) was used to cleave peptides off the resin. 
Crude peptides were purified through Xbridge Peptide BEH C18 column (10 µm, 10 mm × 250 
mm) and analyzed by Eclipse XDB-C18 (5 µm, 4.6 mm × 250 mm) column. The purified peptides 
are identified by HPLC and MALDI-TOF MS (Figure S1). The peptides were dissolved in ddH2O 
at a concentration of 10 mM and stored at -80°C. Wang resins were purchased from Novabiochem, 
and the Fmoc protected amino acids were purchased from Chempep. 
1.4.4  Enzymatic synthesis and purification of glycopeptide  
The reactions were performed at 37 °C for 2 h, in a total volume of 100 µL solutions 
containing 1 mM peptide, 3 mM UDP-GlcNAc analogs, 50 µg ncOGT in buffer (50 mM Tris-HCl, 
pH 7.5, 10 mM Mg2+). The reaction mixtures were boiled for 10 min and centrifuged at 12, 000 g 
for 30 min to remove the enzyme. The reaction mixture (100 µL) was diluted with 100 µl de-
ionized water and ready for HPLC separation. 
Each sample was detected on an Agilent HPLC equipped with an Eclipse XDB-C18 
Column (5 µm, 9.4 * 250 mm). The separation was carried out at a mobile phase gradient (mobile 
phase A: 100 % H2O, 0.1 % TFA; mobile phase B: 100 % ACN and 0.1 % TFA) of 5 % to 35 % 
B in 30 min at a flow rate of 2.5 ml/min. The detection wavelength was set at 220 nm. The yield 
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was calculated through the formula Y= S1/ (S1+S2), where S1 and S2 stand for integrated areas 
of the product peak and substrate peak, respectively. HPLC analysis was performed in triplicate.  
1.4.5  OGA substrate specificity assay  
The glycopeptide peaks were collected from above HPLC seperation, lyophilized and 
dissolved in buffer (50 mM Tris-HCI, pH 7.5, 10 mM Mg2+). The reactions were performed at 37 
°C overnight, in a total volume of 100 µL solutions containing glycopeptide and 100 µg OGA. The 
reaction mixtures were boiled for 10 min and centrifuged at 12, 000g for 30 min to remove the 
enzyme before HPLC separation. 
1.5   Conclusion and significance 
Glycopeptides containing different GlcNAc derivatives were successfully synthesized in a 
recombinant full-length hOGT-catalyzed reaction using chemoenzymatically synthesized UDP-
GlcNAc derivatives. We also found that full-length hOGT is a more efficient catalyst than sOGT, 
as over 49-fold yield was observed when hOGT was used. The resulting glycopeptides were used 
to investigate the substrate specificity of hOGA towards the sugar moiety. hOGA was less 
promiscuous in tolerating glycopeptide substrates with modified GlcNAc, and changes in the C2, 
C4, and C6 positions of GlcNAc partially affected its recognition. Interestingly, OGT and OGA 
possessed different levels of tolerance to the same sugar moiety, such as GlcNPh, GlcNTFA, and 
4-OMe-GlcNAc. Therefore, the acquired GlcNAc derivatives, which were well-recognized by 
OGT but not hydrolyzed by OGA, may increase the O-GlcNAcylation level in vivo when the 
peracetylated compound is metabolically incorporated. Indeed, our group developed an OGA-
resistant probe, peracetylated 4-deoxy-N-azidoacetylglucosamine (Ac3-4-Deoxy-GlcNAz), which 
can be used as a potent tool for O-GlcNAcylation detection and the identification of O-
24 
GlcNAcylated proteins38. Thus, OGA-resistant GlcNAc substrates show potential as excellent 
probes for investigating O-GlcNAcylation and elucidating their importance in cellular events. 
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2   BIOMARKER-BASED METABOLIC GLYCAN LABELING FOR 
REDIRECTED AND ENHANCED IMMUNE RESPONSE 
2.1   Introduction  
2.1.1  Redirecting or enhancing immune responses 
Redirecting or enhancing immune responses towards otherwise immune inert targets has 
emerged as an attractive therapeutic strategy. Compared with small-molecule-based therapeutics, 
this strategy shows increased selectivity and decreased side effect caused by “off-target” effect. 
By stimulating immune system, this approach has the potential to develop long-lasting adaptive 
effect 46-47 and zeroing in on otherwise “undruggable” targets.48-50 Furthermore, many diseases 
develop because of the ability for abnormal cells to escape host immunity.51-52 In this case, 
redirecting or enhancing immune responses towards such “escaped” pathogens, broadly defined, 
can be an effective therapeutic method.  
Redirecting or enhancing immune responses towards otherwise immune inert targets 
usually include two steps: 1) labeling the targets with a moiety which can stimulate immune system 
and recruit antibody (Also called hapten). Such a moiety can mark the targets as “permit to kill” 
and recruit antibodies when they are tethered to cells.  2), Antibody recruitment and targets 
destruction by complement-dependent cytotoxicity (CDC) and antibody-dependent cellular 
phagocytosis (ADCP) (Fig 2.1). CDC was initiated by the antibody binding, which leads to the 
activation of complement cascade and the formation of membrane attack complex pores. This 
event was followed by direct target cell lysis or complement-receptor-expressing effector cells 
binding, and finally leading to target the cell death. Alternatively, binding to the Fc fragment of 
antibody, Fc-receptors expressed immune cells can lead to target cell phagocytosis (ADCP) or the 
release of potent oxidizing agents and protein toxins (ADCC).53  
31 
 
Figure 2.1 Immune system was activated by hapten introduction on the cell surface of 
target pathogen. 
Hapten introduction on target pathogen surface leads to the antibody recruitment. Initiated 
by antibody binding, the complement cascade was activated leading to the pathogen destruction 
by CDC; Another way is that the Fc-receptor expressing immune cells, such as macrophage, are 
able to bind with the antibody, thus causing pathogen death by ADCP. 
  
The key challenge in this immune therapy is the selective installation of a moiety (also 
called a hapten) on the surface of target cells for the recruitment of immune responses. Antibody 
recruiting molecules (ARMs) are synthetic bi-functional molecules containing a target-binding 
terminus (TBT), which recognize surface receptors of the target cell and antibody-binding 
terminus (ABT), which can recruit antibodies and activate immune responses. Using ARMs, the 
therapeutic effects of redirecting or enhancing immune responses towards otherwise immune-inert 
targets have been demonstrated in disease models such as cancer,48 bacterial infection54 and virus 
infection.55-56 However, immune therapy utilizing ARMs faces several challenges. Existing ARMs 
rely on their ability to bind with a target noncovalently, which requires careful design of the ARMs 
to ensure high affinity between the TBT component and surface receptor. Further, the binding of 












which would abolish its ability to recruit antibodies and to activate immune responses. Other 
strategies such as direct installation of hapten through hapten-conjugated sialic acids also showed 
promising therapeutic effects. In such a case, the hapten is covalently attached to sialic acids, which 
can be expressed on the cell surface by metabolic labeling. The hapten-conjugated sialic acids need 
to be recognized by a cellular sialylation pathway, which may put a limitation of the hapten type, 
size, and number that sialic acids can carry. 
Our labs have had a long-standing interest in carbohydrate-mediated selective recognition 
and immune responses, herein we combined our strength and described a new strategy allowing 
for covalent and stable glycan engineering to recruit antibodies for redirected and enhanced 
immune response. This novel strategy takes advantage of metabolic glycan labeling (MGL) and 
folate induced endocytosis for selective delivery of cargos to cancer cells, which will be discussed 
in detail below. 
2.1.2  Glycan engineering tool: metabolic glycan labeling (MGL) 
The metabolic glycan labeling (MGL) has recently emerged as a powerful tool for glycan 
imaging, enrichment and glycomics analysis, which utilizes the intrinsic glycan metabolism to 
introduce unnatural glycans bearing various chemical groups such as alkynes, azides onto cell 
surface.57 Bertozzi’s group first reported the two-step labeling techniques with unnatural sugar 
mannosamine (ManNAz): (1) the ManNAz was used to fed cells for glycan metabolism and 
displayed on the cell surface and (2) bioorthogonal click molecules could be chemically bound to 
the unnatural glycans by click chemistry (Fig 2.2). Later on, several unnatural monosaccharides, 
including Gluocosamine (GlcNAc)58-60, galactosamine (GalNAc)61, sialic acid62 and Fucose63, 
have been successfully incorporated onto glycoproteins in cells and living animals. This glycan 
33 
engineering method  has been widely used in both in vitro and in vivo for research and therapeutic 
applications.  
 
Figure 2.2 Strategy for metabolic glycan labeling (MGL) and fluorophore labeling via 
click chemistry. 
After passive diffusion and deacetylation, ManNAz was able to enter the sialic acid 
biosynthesis pathway, and finally display on the cell surface. Fluorophore conjugated 
bioorthogonal click molecules could be used for sugar detection and visualization.  
 
The Glycan engineering method discovered in Bertozzi’s group utilizing sialic acid 
biosynthesis pathway (Fig 2.3). Sialic acids, a family of nine carbon monosaccharides, are widely 
locate in higher eukaryotes and certain microbes and often reside at the outmost end of cell-surface 
glycans.5 N-Acetylmannosamine (ManNAc) is synthesized from UDP-N-acetylglucosamine 
(UDP-GlcNAc) through of UDP-GlcNAc 2-epimerase. ManNAc is phosphorylated to ManNAc-
6-phosphate (ManNAc-6-P), which is subsequently condensed with phosphoenolpyruvate (PEP) 
to yield sialic acid-9-phosphate (sialic acid-9-P). Dephosphorylation of sialic acid-9-P results in 
sialic acid. Sialic acid is transported into the nucleus, where it is activated to CMP-sialic acid by 
the CMP-sialic acid synthase. CMP-sialic acid is then transported into the Golgi apparatus and 

















Figure 2.3 The de novo biosynthetic pathway of sialic acid. 
  
However, different MGL efficiencies may occur with different unnatural sugars or within 
different cell lines. For example, after treated with Ac4ManNAz (Fig 2.4 A), Jurkat cells have the 
highest incorporation efficiency (41 % of total sialic acid was labeled with azido group), followed 
by CHO (29 %) and COS-7 cells (5 %).65 In every cell line, MGL efficiency with Ac4ManNAl 
(Fig 2.4 B) was substantially more efficient than with Ac4ManNAz. For example, in the human 
prostate cancer cell line LNCaP, 78 % of sialylated glycoconjugate were substituted with alkyne 
group compared with 51 % with Ac4ManNAz.66 After studying the efficiencies of different 
unnatural sugars, the MGL dynamic question was raised: how long does it take for a 



































































group monitored this dynamic progress and answered this question in 2008.67 They monitored the 
conversion of Ac4ManNAl into the corresponding sialic acid analogue and its integration into cell-
surface glycans, and found out that the increase of cell-associated fluorescence was detected as 
early as 75 min after the cells were treated with Ac4ManNAl. Moreover, they proved that 30 min 
was estimated for a peracylated molecule to diffuse across the plasma membrane and its ester 
protecting groups to be hydrolyzed by nonspecific esterase, however, it may take approximately 
another 45 min to convert the liberated ManNAl into the alkyne-bearing sialic acid and to 
incorporate it into cell surface glycans. 
 
Figure 2.4 Structures of Ac4ManNAz and Ac4ManNAl. 
 
2.1.3  Cell-selective metabolic glycan labeling (SMGL) 
As described above, the drawback of the MGL is that the unnatural sugar probes exhibit 
the similar manner on the surface of both normal and tumor cells, resulting in the low specificity 
against tumor cells in vivo. For example, the treatment of mice with peracetylated N-
azidoacetylmannosamine (Ac4ManNAz) results in the widespread labeling of glycans in numerous 
tissues such as the brain, kidney and heart. The broad distribution of the azidosugar fails to find 
out the glycomic changes in a single organ or tumor tissues. One way to lead the tissue or tumor 
selectivity in glycan imaging is to direct the distribution of azidosugar to the cells of interest. A 
few groups have reported the targeted glycan imaging technologies. Endogenous cancer 
overexpressed enzymes can be used to achieve selective labeling of cancer cells over normal cells.  














targeting release against metabolic precursors caged with enzyme substrate (Fig 2.5 A). The caged 
precursors will retain intact until the specific enzyme cleave off the linkage and set sugar free in 
tumor tissue. For example, the Bertozzi’s  group introduced a caged metabolic precursor with a 
prostate-specific antigen (PSA) specific cleavable peptide substrate.68 The caged metabolic 
precursor showed high-specificity for the targeted prostate tumor cells in the cell culture system. 
 
Figure 2.5 Strategies for cell-selective metabolic glycan labeling (SMGL) via enzyme 
cleavage or ligand-targeted liposomal delivery. 
 
Later, Kwangmeyung Kim’s group developed a cathepsin B-specific cleavable peptide-











































target tumor cells.69 And Cheng’s group designed a dual-enzymatically triggering MGL to improve 
the cancer selectivity.70 The other tool to achieve this was developed by Chen’s group based on 
the liposomal delivery strategy (Fig 2.5 B). The azidosugars were encapsulated in ligand-targeted 
liposomes which bind to cancer overexpressed cell-surface receptors and then endocytosed into 
cells.71 Although these elegant methods have proven useful in studying cell surface glycans, 
information regarding cell-selective metabolic glycan labeling (SMGL) is still limited. Novel 
metabolic probes with tumor cell targeting selectivity are urgently needed in imaging and 
therapeutics. 
2.1.4  Folic acid conjugated azidosugar for SMGL 
 
Figure 2.6 FR endocytosis and trafficking process. 
FR was internalized into cells with folic acid conjugates binding. Upon dissociation, folic 
acid conjugates were cleaved by high concentrations of GSH, the liberated azidosugar can enter 
the glycan biosynthesis pathway. The FR receptors will recycle back to cell surface for the new 
round of FR endocytosis and trafficking process. (The figure is presented in a qualitative way 















In this project, we are interested in a very reliable way of targeted delivery. Many forms of 
cancer,  ovary, uterus, breast and kidney, are known to over-express high-affinity folate receptor 
(FR).72-74 The utility of folic acid as ligand has arisen from its ease conjugation to other agents, 
high affinity for the folate receptor (Kd =10-10 M), and the limited distribution in normal cells and 
tissues.75 FR endocytosis and trafficking process with folic acid conjugated azidosugar is 
illustrated in  Fig 2.6. After binding to FR on the cancer cell surface, folic acid conjugates are 
shown to internalize into intracellular endosomes which have pH values between 4.3 and 6.9. Thus, 
some of the folic acid conjugates will dissociate from their receptors because of the low binding 
affinity of folic acid to its receptor at pH under 5.76 The folic acid conjugates are linked through 
disulfide linkage which can be cleaved upon high GSH concentration in cancer cells, after which 
the azidosugar can be released and enter the glycan biosynthesis pathway. The receptors would 
recycle back to the cell surface in 8-12 h for next round of trafficking.75, 77. 
Thus, FR has been an appealing target as a means for tumor-specific delivery of drug 
therapies for over a decade.78 For example, folate-maytansine DM1 and folate-camptothecin, could 
kill a panel of FR overexpressed cancer cells with IC50 values between 10-11 and 10-10 M, 
suggesting efficient drug release following FR endocytosis.79 Many other folate-conjugated 
prodrugs have been evaluated in animal models, and several have reached various stages of human 
clinical trials.80-81 As a result, we decided to use folate conjugates as a way to achieve selective 
metabolic labeling, and then to selectively destruct cancer cells by redirecting or enhancing the 
immune response.  
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2.2   Objectives and general scheme 
 
Figure 2.7 General strategy to redirect or enhance immune responses toward a desired 
target. 
 
The general idea of this new strategy is shown in Fig 2.7. First, folic acid conjugated 
azidosugar is delivered to the target cells, for eventual cell surface metabolic labeling. Then a 
hapten is introduced to the cell surface via click chemistry. Subsequently, the hapten “recruits” 
antibodies, leading to target destruction by ADCP and /or CDC. This strategy of covalently 
tethering the hapten to the target cells is expected to allow for stable tagging and thus long-term 
effect of “being marked” for destruction. It should be noted that many pathogenic targets, such as 
cancer cells and bacteria can be labeled with an azidosugar, so this strategy can be used to target 
various pathogens. Furthermore, there are many other receptors to exploit for this kind of 
intracellular delivery of azidosugar. Thus, it is conceivable that this approaches can be used to 
target cells of different disease relevance. 
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Scheme 1 Structure of f-PEG-Mz and its Ac3ManNAz release mechanism. 
 
We designed folate-PEG (Polyethylene glycol)-Ac3ManNAz (f-PEG-Mz) for folate 
receptor-mediated uptake of Ac3ManNAz (Scheme 1). Folate is conjugated to the sugar via a 
disulfide cleavable linker, which can be activated by free thiol species known to be abundant inside 
cancer cells. As such, Ac3ManNAz is converted to cell surface glycan bearing an azido group, 
which serves as an anchor to introduce the antibody-recruiting molecules (ARMs) to recuite 
antibody accumulation. There have been many reported haptens used for antibody recruitment 
such as Gal-α(1,3)-Gal-β(1,4)-GlcNAc/Glc (α-Gal),82-83 L-rhamnose (Rha), 84-87 2,4-dinitrophenyl 
(DNP)88 and phosphorylcholine (PC).89 The reason why we choose Rha as the antibody recuiting 
moiety is that others and we have demonstrated the relatively high antibody titers for Rha in human 
serum.90-92 We decided to use the Strain-Promoted Azide-lkyne Click Chemistry (SPAAC) 
reaction to avoid Cu toxicity. The reaction between aza-dibenzocyclooctyne (DBCO) and an azido 
group is among one of the fastest SPAAC and has been widely used in labeling and imaging work. 
93-95  Thus, we chose DBCO to link Rha to the azidosugar in the cell surface and synthesized 





Scheme 2 Structure of DBCO-Rna. 
 
2.3   Results and discussion  
2.3.1  f-PEG-Mz stability assay  
The release profile and stability of f-PEG-Mz were studied by HPLC (Fig 2.8). When 100 
µM f-PEG-Mz was incubated with 10 mM of glutathione (GSH) in phosphate-buffered saline 
(PBS, pH = 7.4), a concentration similar to those reported in cancer cells, more than 90% free 
Ac3ManNAz was released within 4 h. In contrast, when f-PEG-Mz was incubated with 300 µM 
GSH in PBS, a plasma relevant concentration, less than 5 % free Ac3ManNAz was observed after 
24 h. These results showed f-PEG-Mz should be stable during the circulation and yet readily 



















Figure 2.8 In vitro f-PEG-Mz stability assay when treated with 300 µM or 10 mM GSH. 
 
2.3.2  Cell models generation with different folate receptor expression level 
To investigate whether f-PEG-Mz could be employed to selectively target folate receptor 
(FR)-overexpressed cells, three cell lines were chosen to represent scenarios of no, low and high 
FR expression, respectively (Fig 2.9 A). KB cells were originally thought to be oral epidermal 
carcinoma, but later researchers found this cell line was Hela (cervix adenocarcinoma cell line) 
contaminated.96 Though people have shown that KB cell line was contaminated, it was still widely 
used as a model for folate receptor study.71, 74 FR+ KB cells were built by culturing KB cells in a 
folate-depleted medium supplemented with dialyzed FBS for ten passages.97 MCF7, a breast 
cancer cell line with no folate receptor expression, was used together with KB and FR+ KB cells 
to represent no, low and high FR expression. FR expression was detected by Western blot. 

























normal medium, FR+ KB showed a dramatically increase in FR expression (Fig 2.9 B). The results 
showed the success in the generation of cell lines with different FR expression level. 
 
Figure 2.9 Illustration of folate receptor-mediated azidosugar selective uptake. 
 (A) Three cell line models for folate receptor-mediated ManNAz selective uptake. MGL : 
metabolic glycan labeling. (B) FR expression level revealed by Western blot.  
 
2.3.3  Metabolic glycan labeling by f-PEG-Mz in FR+ KB cells 
The dynamic manner of f-PEG-Mz uptake in FR+ KB cell line was analyzed by flow 
cytometry. FR+ KB cells were treated with various concentrations (0, 6, 12, 25, 50, 100 µM) of f-
PEG-Mz for 48 h, and labeled with DBCO-Carboxyrhodamine 110 (DBCO-CRA, DBCO 
conjugated with a green fluorophore). The f-PEG-Mz uptake showed a concentration-dependent 
manner, and clear fluorescence labeling can be detected with the mimimum concentration of 25 
µM f-PEG-Mz (Fig 2.10). Then, cells were treated with 50 µM f-PEG-Mz for various incubation 
times and then labeled the cells with DBCO-CRA. There was a time-dependent increase in 
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showed that f-PEG-Mz could be efficiently  taken by FR+ KB cells and released free azido sugar 
inside cells. 
 
Figure 2.10 Concentration- dependent and time-dependent azidosugar display on cell 
surface via f-PEG-Mz uptake and metabolic labeling. 
FR+ KB cells were incubated with different concentrations of f-PEG-Mz for various times, 
then cells were then washed and labeled with DBCO-CRA fluorophore and analyzed by flow 
cytometry. 
 
2.3.4  The selectivity of f-PEG-Mz uptake and azidosugar labeling 
We then tested the selectivity of FR-mediated delivery towards FR overexpressed cells. 
KB and FR+ KB cells were treated with various concentrations (0, 6, 12, 25, 50, 100 µM) of f-
PEG-Mz for 48 h. Cells were then washed and labeled with DBCO-CRA. The fluorescence 
intensity of the labeled FR+ KB cells was 2 to 5-fold higher than that of the KB cells (Fig 2.11 A). 
Such results indicated that over-expression of FR led to increased uptake of f-PEG-Mz and 
subsequently increased glycan labeling. We collected cell lysates of FR+ KB cells and KB cells 
after 48 h treatment of 50 µM f-PEG-Mz, and characterized with Western blot. FR+ KB cells with 
f-PEG-Mz treatment showed significant higher band intensity compared with KB cells (Fig 2.11 
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same labeling efficiency in both cell lines, indicating that both FR+ KB and KB cells have the same 
ability in incorporating ManNAz into surface azidoglycan without selectivity (Fig 2.11 B, band 5 
and 9). The negative control Ac4ManNAc (Fig 2.11 B, band 2 and 8) and folate-polyethylene 
glycol (f-PEG, Fig 2.11 B, band 3 and 11) showed similar band intensity as the non-treatment 
group (Fig 2.11 B, band 1 and 7). In summary, the data demonstrated that f-PEG-Mz uptake and 
azidosugar labeling was cell-selective, depending on the FR expression level. 
 
Figure 2.11 Cell-selective metabolic labeling by f-PEG-Mz uptake and azidosugar 
labeling. 
 (A) Flow cytometry analysis of f-PEG-Mz uptake difference in KB and FR+ KB cells. KB 
and FR+ KB cells were treated with indicated concentrations of f-PEG-Mz for 48 h at 37 °C; cells 
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KB and FR+ KB cells revealed by Western blot. KB and FR+ KB cells were treated with 50 µM of 
different compounds for 48 h at 37 °C, lysed, labeled with DBCO-biotin and characterized with 
Western blot against streptavidin-HRP antibody. 1, 7: non-treatment group; 2, 8: Ac4ManNAc ; 
3, 11:  folate-polyethylene glycol (f-PEG); 4, 10: f-PEG-Mz; 5, 9: Ac4ManNAz. 
 
 
Figure 2.12 Confocal fluorescence imaging of different compounds in FR+KB cells. 
FR+ KB cells were cultured with 50 µM f-PEG-Mz, Ac4ManNAz or f-PEG for 48 h, then 
cells were dyed with DBCO-RA (azide signal), LK26 and PE conjugated secondary antibody 
(folate receptor signal), and DAPI stain (nuclear signal), after which cell fluorescence images 
were taken. Scale bar: 5 µm.    
 
We also used confocal fluorescence microscopy to examine the selective presentation of 
azidosugar through f-PEG-Mz uptake. First, we had positive compound (Ac4ManNAz) and 
negative compound (f-PEG) to control the performance of f-PEG-Mz. Cells were treated with 50 
µM f-PEG-Mz, Ac4ManNAz or f-PEG at 37 °C for 48 h, followed by the DBCO-CRA labeling to 
the cell surface azidosugar, anti-folate binding protein antibody (LK26) and goat anti-mouse IgG 
H&L Phycoerythrin (PE conjugated secondary antibody) labeling to the folate receptor. Thus, red 
fluorescence represents the FR signal, green fluorescence shows the azide signal and blue 








fluorescence was the nuclear signal.  As shown in Fig 2.12, equal FR signal was observed in three 
groups. Strong and equal azide signal was observed with f-PEG-Mz and Ac4ManNAz treatment, 
whereas almost no azide signal was observed with f-PEG treatment. Second, we examined the 
selectivity of f-PEG-Mz in three cell lines with different FR expressions. FR+ KB cells treated with 
f-PEG-Mz displayed clear cell surface FR signal and azide signal (Fig 2.13, 2 and 3), whereas 
much weaker fluorescence was observed in KB cells (Fig 2.13, 6 and 7). For the MCF7 cells, there 
was neither azide nor FR fluorescent labeling (Fig 2.13, 10 and 11). These results unambiguously 
demonstrated that f-PEG-Mz uptake was an FR-mediated process and f-PEG-Mz was able to 
differentiate cells with different FR expression levels.  
 
Figure 2.13 Confocal fluorescence imaging of different cell lines fed with f-PEG-Mz. 
FR+ KB, KB, and MCF7 cells were cultured with 50 µM f-PEG-Mz for 48 h, then cells 
were dyed with DBCO-CRA (azide signal), LK26 and PE conjugated secondary antibody (folate 
receptor signal), and DAPI stain (nuclear signal), after which cell fluorescence images were taken. 
Scale bar: 5 µm.    
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2.3.5  Validation the cell selectivity of f-PEG-Mz labeling in co-culture system 
Specifically, MCF7 was co-cultured with FR+ KB cells overnight at 1:1 ratio, followed by 
incubation with 50 µM of f-PEG-Mz for 48 h. Cells were then collected, washed, and stained with 
DBCO-CRA, LK26 and PE conjugated secondary antibody for confocal fluorescence microscopy. 
It was observed that f-PEG-Mz only led to significant incorporation of azidoglycan in FR+ KB 
cells, thus strong green fluorescence, affording clear differentiation of the two cell lines (Fig 2.14 
A). Next, we quantified the fluorescence intensity with flow cytometry (Fig 2.14 B). Similarly, f-
PEG-Mz treatment resulted in considerable fluorescence signal differences between FR+ KB and 
MCF7 cells, and a positive correlation between the FR signal and azide signal. Both types of cells 
gave similar signal intensity with Ac4ManNAz treatment although FR+ KB showed slightly higher 
FR signal (Figure 2.14 B), presumably through non-selective passive permeation of Ac4ManNAz. 
As a control, cells treated with f-PEG showed very weak basal level of fluorescence intensity 
(Figure 2.14 B), a reflection of the low level of azidosugar incorporation. These results suggested 
that f-PEG-Mz was an efficient and selective metabolic precursor to selectively label cells 
expressing the folate receptor. 
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Figure 2.14 Cell-selectivity of f-PEG-Mz in co-culture system. 
 (A) Confocal imagine of co-cultured cell lines fed with f-PEG-Mz. FR+ KB and MCF7 
cells were cultured, and incubated with 50 µM f-PEG-Mz for 48 h, then cells were dyed as above 
for cell fluorescence image. Scale bar: 10 µm. (B) Flow cytometry of co-cultured cell lines fed with 





























2.3.6  HPLC study of DBCO-Rha reactivity  
 
Figure 2.15 HPLC profiles of DBCO-Rha (upper panel) and its reaction with 
Ac3ManNAz (lower panel). 
 
To demonstrate the initial feasibility of the strategy described, we first examined the ability 
to present cell surface azidosugar and the possibility of tethering a hapten unit through click 
chemistry to cell surface azidosugar, and thus inducing antibody-mediated responses. First, the 
DBCO-Rha reactivity was studied in vitro by HPLC (Fig 2.15). To 1 mL of PBS was added 25µM 
DBCO-Rha solution and 250 µM 1, 3, 4-O-Acetyl-N-azidoacetylmannosamine (Ac3ManNAz) 
solution. The reaction mixture was incubated at 37 °C for 30 min; then 20 µL sample was analyzed 
by LC-MS. 25 µM DBCO-Rha was fully consumed within 30 min at 37 °C in the presence of 250 
µM Ac3ManNAz. The retention time for the product, Ac3ManNAz-DBCO-Rha, was 2.8 min (Fig 
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2.15). The HRMS of Ac3ManNAz-DBCO-Rha was calculated as C58H80N8O23Na, [M+Na]+ = 
1279.5229, and was found as 1279.5257.  
2.3.7  Cell selective Rha display on cell surface via f-PEG-Mz labeling and DBCO-Rha 
coupling 
 
Figure 2.16 Cell-selective display of Rha via f-PEG-Mz labeling and DBCO-Rha 
coupling. 
 (A) Concentration-dependent Rha display.  FR+ KB cells were incubated with indicated 
concentrations of f-PEG-Mz for 48 h, and then 50 µM DBCO-Rha for 1h. After which cells were 
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Fluorescence intensity was measured by flow cytometry. (A) Cell-selective Rha display. FR+ KB, 
KB, MCF7 cells, and HEK-293 cells were cultured with 50 µM f-PEG-Mz for 48 h, and then 50 
µM DBCO-Rha for 1h. After which cells were labeled and analyzed by flow cytometry as above. 
One-way ANOVA. ***p < 0.001, **p < 0.01 as compared to FR+ KB cells. n= 3 biological 
replicates. 
 
We then tested if this novel “delivery, label, and recruit” strategy would lead to the 
selective destruction of cells based on FR expression. FR+ KB cells were incubated with various 
concentrations of f-PEG-Mz for 48 h, and then washed and reacted with 50 µM DBCO-Rha for 2 
h at 37 °C. To measure the amount of Rha displayed on the surface, cells were then incubated with 
anti-Rha for 1 h, followed by anti-human PE-conjugated secondary antibody for 1.5 h. The 
fluorescence intensity, which represents the amount of Rha on the surface, was then measured by 
flow cytometry. f-PEG-Mz concentration-dependent displaying of Rha on the surface of FR+ KB 
cells was observed (Figure 2.16 A). We also used additional cell lines. Specifically, FR+ KB, KB, 
MCF7, and HEK-293 cells were treated with f-PEG-Mz and DBCO-Rha, and the amounts of Rha 
on their surface were determined by the method as above. HEK-293 is a human embryonic kidney 
cell line, which lacks FR expression. As shown in Figure 2.16 B, FR+ KB cells showed the 
strongest fluorescence intensity among these four cell lines. MCF7 and HEK-293 cells showed 
negligible fluorescence signal because of the lack of FR. The above data showed that the 
combination of f-PEG-Mz and DBCO-Rha led to the selective and efficient display of Rha on cell 
surface that over-express the FR. 
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2.3.8  Complement-dependent cytotoxicity (CDC) 
 
Figure 2.17 Rational of complement-dependent cytotoxicity (CDC) experiment.  
After which the cells were labeled with azidosugar via f-PEG-Mz and introduced Rha 
residues on the cell surface via DBCO-Rha, we treated the cells with human serum which supplied 
anti-rhamnose antibody, and also complement to initiate the CDC. MGL*, metabolic glycan 
labeling. 
 
The displayed Rha functions as a hapten, which can mark the targets as “permit to kill” and 
recruit anti-Rha antibodies (Fig 2.17). CDC was initiated by the anti-Rha antibody binding, which 
leads to the activation of complement cascade and the formation of membrane attack complex 
pores. This event was followed by direct target cell lysis or complement-receptor-expressing 
effector cells binding, and finally leading to target cell death.  
Target pathogen
* metabolic glycan labeling










Figure 2.18 Cell selective CDC. 
FR+ KB, KB, MCF7 and HEK-293 cells were cultured with 50 µM f-PEG-Mz for 48 h and 
50 µM DBCO-Rha for 1 h. Cells were then treated with 20% human serum and human complement 
for 4 h at 37°C. * provide anti-rhamnose antibody. 
 
In order to confirm the event of CDC, FR+ KB, KB, MCF7, and HEK-293 cells were 
incubated with 50 µM f-PEG-Mz for 48 h, and then washed and labeled by 50 µM DBCO-Rha for 
1 h. Subsequently, cells were treated with 20% human serum and human complement for 4 h at 37 
°C. Cell viability was then determined by Cell counting kit-8. The main compound of  CCK-8 
was WST-8.98 WST-8 is reduced outside of a cell via the plasma membrane electron transport and 
electron mediator to give an orange colored product, which is soluble in the tissue culture medium. 
The amount of the formazan dye generated is directly proportional to the number of living cells. 
As shown in Fig 2.18, about 50% of the labeled FR+ KB cells were killed; while 20% of KB cells 
were killed. MCF7 and HEK-293 cells showed negligible viability change. Such results were in 
agreement with the relative levels of FR expression in various cell lines, and demonstrated that 
selective delivery of Ac3ManNAz using f-PEG-Mz followed by the display of Rha via DBCO-Rha 
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+ 20% human serum *
FR+
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2.3.9  Antibody-dependent cellular phagocytosis (ADCP) 
Alternatively, binding to the Fc fragment of antibody, Fc-receptor expressed immune cells 
can lead to target cell phagocytosis. The ADCP was initiated by the activated THP-1 cells binding 
to anti-Rha antibodies, leading to the phagocytosis of Rha labeled target cells. Thus, we were 
interested in testing if the installation of Rha on the cell surface would lead to cell killing by ADCP.  
 
Figure 2.19 ADCP induced by f-PEG-Mz and DBCO-Rha. 
FR+ KB cells were treated with 50 µM indicated compounds for 48 h, then 50 µM DBCO-
Rha and 5 µg/mL anti-Rha antibodies subsequently. In “no Rha” group, cells were treated with 
50 µM f-PEG-Mz for 48 h, however, DBCO-Rha was not applied. Cells were dyed with DiO green 
dye and mixed with 2 x 105 THP-1 cells (Dyed with DiD red dye) at 1：1 ratio for 3 h, after which 
the cell mixture was subjected to flow cytometry. The % ADCP was indicated by the percentage of 
dual color labeled cells. One-way ANOVA. ****p < 0.0001, ns > 0.05 as compared to “no Rha” 
control. 
 
To test this idea, FR+ KB cells were treated with 50 µM Ac4ManNAc, f-PEG-Mz or 
Ac4ManNAz for 48 h, followed by reacting with DBCO-Rha for 2 h and then with 5 µg/mL anti-
Rha antibody (purified from human serum as described previously)99  for 1 h.  FR+ KB cells 
were then washed and labeled with Vybrant DiO cell-labeling solution. THP-1 cells were 
differentiated and induced using 100 ng/mL of phorbol 12-myristate 13-acetate (PMA) for 48 h. 


















of lipophilic fluorescent dyes for cell membranes and other hydrophobic structures.100 The 
fluorescence of these dyes are weakly fluorescent in water. Once applied to cells, these dyes diffuse 
quickly within the cellular plasma membranes, resulting in even staining of entire cell at optimal 
concentrations. Both FR+ KB and THP-1 cells were washed with PBS three times to remove excess 
dyes. FR+ KB cells were mixed with THP-1 cells at 1:1 ratio for 3 h. The THP-1 cells can be 
activated by the anti-Rha antibody displayed on the surface of FR+ KB cells, resulting in ADCP. 
Then ADCP was determined by using flow cytometry to detect the THP-1 cells with both red and 
green fluorescence. As negative controls, cells treated with Ac4ManNAc or with f-PEG-Mz but 
without subsequent DBCO-Rha treatment showed basal level ADCP. Cells treated with f-PEG-
Mz or Ac4ManNAz showed almost 3-fold ADCP rate compared with the control group (Fig 2.19). 
ADCP was also directly observed by fluorescence imaging. After f-PEG-Mz, DBCO-Rha and anti-
Rha antibody treatment, FR+ KB cells (green fluorescence) were mixed with THP-1 cells (red 
fluorescence). ADCP of FR+ KB by THP-1 cells was clearly observed by the brownish 
fluorescence, which is the result of mixing green and red fluorescence (Fig 2.20).  
 
 
Figure 2.20 Fluorescence image of FR+ KB cells phagocytosed by THP-1 cells. 
FR+ KB cells were treated with 50 µM f-PEG-Mz for 48 h, then 50 µM DBCO-Rha and 5 
µg/mL anti-Rha antibodies subsequently. FR+ KB cells were dyed with DiO green dye and mixed 




THP-1 cells with 
endocytosed FR+ KB 
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mixture was subjected to microscopy. (a) DiO green dye which shows the signal of FR+ KB cells, 
(b) DiD red dye which shows the signal of THP-1 cells, (c) THP-1 cells with FR+ KB cells 
phagocytosis were shown in merged yellow color. Scale bar: 20 µm. Pearson correlation 
coefficient r=0.976. 
 
2.4   Materials and general methods  
2.4.1  Materials used in this project 
Medium for cell culture including RPMI 1640 medium, fetal bovine serum (FBS), 100× 
antibiotic-antimycotic solution, RPMI 1640, folic acid-depleted medium, dialyzed FBS, minimum 
essential medium, glutamine-depleted medium (MEM), DMEM, high glucose (DMEM), and opti-
MEM reduced serum medium were purchased from Gibco. 100 × Halt protease inhibitor cocktail, 
BCA protein assay kit, Vybrant DiO cell-labeling solution, Vybrant DiD cell-labeling solution, 
and antibodies including goat anti-mouse secondary antibody, goat anti-human IgG Fc secondary 
antibody PE conjugated, goat anti-human IgG Fc highly cross-adsorbed secondary antibody HRP 
conjugated were purchased from Thermo Fisher Scientific. Antibodies including anti-folate 
binding protein antibody [LK26], goat anti-mouse IgG H&L Phycoerythrin (PE) conjugated, 
streptavidin-HRP, and goat anti-mouse IgG H&L Phycoerythrin (PE) conjugated, fluoroshield 
mounting medium with DAPI, phorbol 12-myristate 13-acetate (PMA) were purchased from 
Abcam. 16 % formaldehyde (w/v) was from Electron Microscopy Sciences. Millicell EZ 4-well 
slides, 10 kDa centrifugal filter, and 10 × RIPA lysis buffer were purchased from EMD Millipore. 
96-well plates and 6-well plates were purchased from Corning. DBCO-biotin and DBCO- 
carboxyrhodamine 110 (DBCO-CRA) were purchased from Click Chemistry Tools. GSH and 
tetramethylbenzidine (TMB) were purchased from Sigma. CCK-8 was from Dojindo and PVDF 
membrane was from Bio-rad. 
Anti-Rha antibody was purified from human serum following published literature 
procedures.101 
Cell lines used in this study: KB (CCL-17), HEK-293 (CRL-1537), and MCF7 (HTB-22) cells 
were originally purchased from ATCC and were derived from Homo sapiens. FR+ KB cell line 
was developed by culturing KB cells in RPMI 1640, folic acid-depleted medium supplemented 
with 10 % dialyzed FBS for ten passages. 
Compound 8102, compound 968, folate-Polyethylene glycol (f-PEG)103 and 13103 were 
synthesized according to literature procedures. 1H- (400 MHz) and 13C-NMR (100 MHz) spectra 
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were recorded on a Bruker Avance 400 MHz spectrometer. Mass spectrometric analyses were 
performed on an ABI API 3200 (ESI-Triple Quadruple) or MALDI (ABI 4800 Plus TOF / TOF). 
96-well plates were read and recorded on a PerkinElmer 1420 multi-label counter. High-
performance liquid chromatography (HPLC) was performed on a Shimadzu SPD-20A equipped 
with ultraviolet (UV) detector. The HPLC columns used in this work were ZIC®-cHILIC (Merck, 
Darmstadt, Germany). Gel imaging was taken on GE LAS 4000 mini chemiluminescent system. 
Confocal fluorescent images were recorded on Zeiss LSM 700 confocal microscope. Flow 
cytometry was performed on a BD LSRFortessa cell analyzer. 
2.4.2  Design, synthesis and characterization of f-PEG-Mz 
 
Scheme 3 Synthesis route of f-PEG-Mz. 
The synthesis steps of f-PEG-Mz. Reagents and conditions (i) Pyridine, DMAP, 40 ℃,8 
h; (ii)CHCl3, r.t, 72 h; (iii) Et3N, DMSO, r.t, 1 h. 
 
1, 3, 4-O-Acetyl-N-azidoacetylmannosamine -6- (2-(pyridin-2-yldisulfaneyl)ethyl) 
carbonate (10). To a solution of 4-nitrophenyl (2-(pyridin-2-yldisulfanyl)ethyl) carbonate (8, 105 
mg, 0.30 mmol) and  1, 3, 4-O-Acetyl-N-azidoacetylmannosamine (9, 90 mg, 0.23 mmol) in 
anhydrous pyridine (2 mL) was added 4-dimethylaminopyridine (DMAP, 37 mg, 0.30 mmol) at 
r.t. The mixture was stirred at 40 ℃ for 8 h. Then the reaction was quenched with the addition of 
H2O (50 mL) and the mixture was extracted with ethyl acetate (2 × 50 mL). The combined organic 
phase was dried over anhydrous Na2SO4 and evaporated under reduced pressure to give the crude 
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product, which was purified by column chromatography (silica gel, DCM: MeOH = 10:1) to give 
a colorless oil (82 mg, 61 %). 1H NMR (CDCl3): δ 8.46 – 8.45 (m, 1H, aromatic ring), 7.69 – 7.62 
(m, 2H, aromatic ring), 7.11 – 7.08 (m, 1H, aromatic ring), 6.79 (t, J = 11.2 Hz, 1H, proton from 
amide), 6.04 (d, J = 1.6 Hz, 0.5 H, C1 proton from ManNAz), 5.88 (d, J = 1.6 Hz, 0.5H, C1 proton 
from ManNAz), 5.35 – 5.05 (m, 2H, C2-C5 proton from ManNAz), 4.75– 4.60 (m, 1H, C2-C5 
proton from ManNAz), 4.42 – 3.80 (m, 7H, C2-C5 proton from ManNAz, -NHCO-CH2-N3, -S-
CH2-CH2-O- and -S-CH2CH2-OCO-O-), 3.08 – 3.04 (m, 2H, -S-CH2-CH2-O-), 2.16 – 1.99 (m, 9H, 
-OCO-CH3). 13C NMR (CDCl3): δ 171.3, 170.2, 170.2, 169.8, 169.7, 168.4, 168.2, 167.8, 167.3, 
159.6, 154.6, 154.5, 149.8, 149.8, 137.3, 137.3, 121.1, 120.1, 120.1, 91.5, 90.4, 77.4, 73.3, 71.5, 
70.3, 68.9, 66.2, 66.1, 65.4, 65.4, 65.3, 65.2, 60.5, 53.6, 52.6, 52.4, 51.0, 49.8, 49.4, 37.1, 31.7, 
22.8, 21.2, 21.0, 21.0, 21.0, 20.8, 20.8, 20.8, 14.3, 14.2.   HRMS calcd for C22H28N5O11S2 
[M+H]+ 602.1221, found: 602.1221. 
PEG-Mz (12). To a solution of 10 (30 mg, 0.05 mmol) in CHCl3 (0.4 mL) was added NH2-
PEG-SH (MW = 3400, 170 mg, 0.05 mmol) at r.t. The mixture was stirred at r.t. for 72 h. Then 
the solvent was evaporated under reduced pressure to give the crude product, which was directly 
used for the next steps without further purification.  
f-PEG-Mz. To a solution of PEG-Mz (12, 0.05 mmol) and Et3N (30 µL, 0.25 mmol) in 
anhydrous DMSO (0.6 mL) was added folate-NHS (13, 28 mg, 0.05 mmol) at r.t. The mixture was 
stirred at r.t. for 1 h. Then the product was purified on an Agilent HPLC equipped with an Eclipse 
XDB-C18 Column (5 µm, 9.4 × 250 mm). The separation was carried out using a mobile phase 
gradient (mobile phase A: 0.1 % TFA in H2O, mobile phase B: 0.1 % TFA) of 30 % to 60 % B in 




Retention time Area Area% 
4.421 63.77011 3.12 
5.321 24.61662 1.21 
18.883 1952.93079 95.67 
Figure 2.21 HPLC purification of f-PEG-Mz. 
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Figure 2.22 f-PEG-Mz characterized by MALDI (A) and ESI (B). 
 
The f-PEG-Mz were characterized by MALDI and ESI-MS (Fig 2.22). The main peak in 




















































mass of the f-PEG-Mz is a range instead of an exact mass. The main peaks of M/Z in ESI are: 
992.0399, 1005.2006, 1013.5514, and 1058.0789 with z=4. After calculation, the estimated mass 
located exactly in the range of 3600~4600. 
2.4.3  In vitro f-PEG-Mz stability assay 
Stock solution preparation. f-PEG-Mz was dissolved in DMSO to afford a 20 mM stock 
solution; Ac3ManNAz was dissolved in DMSO to afford a 20 mM solution; Glutathione (GSH) 
was dissolved in PBS to afford a 100 mM stock solution. 
Standard curve. To 1 mL PBS was added 1 µL, 2 µL, 3 µL, 4 µL, or 5 µL of 20 mM 
Ac3ManNAz stock solution. Then 20 µL of each sample was injected into Shimadzu Prominence 
UFLC (column: Waters C18 3.5 µM, 4.6×100 mm, injection loop volume: 20 µL). The mobile 
phase was acetonitrile (ACN)/H2O (0-25 min: 20 %-60 % CH3CN; 25- 35 min, 60 %-20 % 
CH3CN; flow rate: 1 mL/min; detection wavelength: 210 nm). The retention time for Ac4ManNAz 
was 5.1 ± 0.2 min. 
f-PEG-Mz treated with different GSH concentration: To 1 mL PBS (containing 300 µM or 
10 mM GSH) was added 5 µL of a 20 mM f-PEG-Mz stock solution. At different time points, 20 
µL of each sample was injected into a Shimadzu Prominence UFLC using the same equipment and 
conditions as described above. 
2.4.4  Cell culture method 
KB cells were cultured in RPMI 1640 medium (Gibco) supplemented with 10 % fetal 
bovine serum (FBS, Gibco) and 0.1 % 100 x antibiotic-antimycotic solution (Gibco). FR+ KB cells 
were cultured in RPMI 1640, folic acid-depleted medium (Gibco) and supplemented with 10 % 
dialyzed FBS (Gibco) and antibiotic-antimycotic solution. MCF7 cells were cultured in the 
minimum essential medium, a glutamine-depleted medium (MEM, Gibco) supplemented with 10 
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% FBS and antibiotic-antimycotic solution. HEK cells were cultured in DMEM, a high glucose 
medium (DMEM, Gibco) supplemented with 10 % FBS and antibiotic-antimycotic solution. All 
cells were maintained in an incubator at 37 °C with 5 % CO2, and allowed for downstream 
experiment until 90 % density. 
2.4.5  Cell surface azidosugar labeling for confocal fluorescence imaging 
For confocal fluorescence microscopy experiment, KB, FR+ KB, and MCF7 cells were 
seeded at a density of about 1.5 x 104 cells /well in Millicell EZ 4-well slides (EMD, Millipore) 
with the medium described in the cell culture method section, respectively. FR+ KB, KB, and 
MCF7 cells were cultured with 50 µM Ac4ManNAz, 50 µM f-PEG-Mz, 50 µM f-PEG, 
respectively, for 48 h. Cells were washed three times with PBS and then incubated with 50 µM 
DBCO-carboxyrhodamine 110 (DBCO-CRA, Click Chemistry Tools) for 30 min at room 
temperature. After washing three times, cells were fixed using 4 % formaldehyde (w/v) (Electron 
Microscopy Sciences, diluted from 16 % formaldehyde) for 15 min at room temperature, followed 
by washing with PBS. Cells were then blocked with block buffer (5 % FBS in PBS), incubated 
with anti-folate binding protein antibody (LK26, Abcam) in dilute buffer (1% FBS in PBS) for 1 
h, and subsequently incubated with goat anti-mouse IgG H&L Phycoerythrin (PE) conjugated 
(Abcam) in dilute buffer for 30 min. After washing with PBS, cells were covered with cover slide 
in the fluoroshield mounting medium with DAPI (Abcam) and incubated at room temperature for 
3 h. Then slides were sealed and stored at 4 °C for future usage. 
2.4.6  Cell surface azidosugar labeling for flow cytometry 
Concentration-dependent: KB and FR+ KB cells were seeded at a density of about 2 x 105 
cells/ well in 6-well plates, and cultured for 24 h in the medium described in the cell culture method 
section, respectively. Then the medium was changed to opti-MEM reduced serum medium (Gibco) 
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and supplemented with various concentrations of f-PEG-Mz (0 µM, 6 µM, 12 µM, 25 µM, 50 µM, 
100 µM) for 48 h incubation. Cells were washed three times with PBS and harvested in the 1.5 
mL Eppendorf tubes with PBS. The incorporated azidosugar displaying on the cell surface was 
clicked with 50 µM DBCO-CRA for 30 min with PBS at room temperature in dark. Cells were 
then washed three times with FACS buffer (1 % BSA in PBS), suspended in 400 µL FACS buffer 
(1 % BSA in PBS), and transferred to the proper tubes for flow cytometry analysis. The sample 
size was 10,000 cells for every flow cytometry measurement.  
Time-dependent: The procedures were similar to the concentration-dependent assay. For 
the time-dependent assay, KB and FR+ KB cells were treated with 50 µM f-PEG-Mz for various 
time points (0, 3 h, 6 h, 12 h, 24 h, 36 h, 48 h). 
2.4.7  F-PEG-Mz uptake difference by Western blot analysis 
KB and FR+ KB cells with different treatment were collected from 6-well plates (Corning) 
after 48 h incubation. The treatment includes non-treatment group, Ac4ManNAc as negative 
control; f-PEG as negative control, 50 µM Ac4ManNAz as positive control and 50 µM f-PEG-Mz. 
Cells were then lysed in the 1× RIPA lysis buffer (EMD Millipore, diluted from 10× in PBS) 
supplemented with 1× Halt protease inhibitor cocktail (Thermo Fisher scientific, diluted from 
100× in lysis buffer), and followed by protein concentration measurement using the BCA protein 
assay kit (Thermo Fisher Scientific). The cell lysates were clicked with 50 µM DBCO-biotin (Click 
Chemistry Tools) for 30 min at room temperature. 10 µg total proteins were loaded onto the gel 
for each sample. The gel was run at 180 V for 45 min. The electrophoresis buffer was prepared at 
10× concentration including 30 g/ L Tris, 144 g/ L glycine, and 10 g/ L SDS. Proteins were further 
transferred to the PVDF membrane (Bio-rad) using iBlot dry blotting system (Thermo Fisher 
Scientific). The membrane was blocked with 3 % BSA in TBST buffer (TBS containing 0.5% 
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(v/v) Tween 20) for 1 h at room temperature with constant shaking. The antibody used for biotin 
detection was streptavidin-HRP (Abcam). The membrane was imaged with Mini Quant 4000 
(Thermo Fisher Scientific). 
2.4.8  Folate receptor expression level in different cells 
MCF7, KB and FR+ KB cells was lysed for Western blot as described above. The antibody 
used was LK26, and the goat anti-mouse secondary antibody (Thermo Fisher Scientific) was 
sequentially applied after membrane washing three times with TBST buffer. The membrane was 
imaged with Mini Quant 4000 (Thermo Fisher Scientific). 
2.4.9  Co-culture for confocal fluorescence imaging 
FR+ KB cells and MCF7 cells were seeded together at a density of about 1.5 x 104 cells / 
well in Millicell EZ 4-well slides with RPMI 1640, folic acid-depleted medium for overnight 
growth. The cells were then treated with 50 µM f-PEG-Mz for 48 h. Cells were dyed and imaged 
as described above in the “2.4.5 cell surface azidosugar labeling for confocal fluorescence 
microscope imaging” session. 
2.4.10   Co-culture for flow cytometry 
FR+ KB cells and MCF7 cells were seeded together at a density of 2 x 105 cells/ well in 6-
well plate with RPMI 1640, folic acid-depleted medium for overnight growth. The cells were then 
treated with 50 µM f-PEG, 50 µM f-PEG-Mz, or 50 µM Ac4ManNAz, respectively, for 48 h. Then 
cells were washed three times with PBS and harvested in the 1.5 mL Eppendorf tubes. Cells were 




2.4.11   Design, synthesis and purification of DBCO-Rha 
 Scheme 4 Synthesis route of DBCO-Rha. 
Reagents and conditions (i) Et3N, diethylphosphorocyanidate, THF, 0 ℃- r.t, 24 h; (ii) 
AcOH/H2O, THF, r.t, 4 h; (iii) BF3/Et2O, THF, 0 ℃- r.t, 48 h; (iv) H2, Pd/C, MeOH, r.t. 3 h; (v) 
MeONa, MeOH, r.t, 3 h; (vi), Et3N, DMF, r.t, 2h. 
 
Benzyl (1,5-bis((4-hydroxybutyl)amino)-1,5-dioxopentan-2-yl)carbamate (3). To a 
solution of ((benzyloxy)carbonyl)glutamic acid (1, 952 mg, 3.4 mmol), 4-((tert-
butyldimethylsilyl)oxy)butan-1-amine ( 2, 1.5 g, 7.5 mmol) and trimethylamine (Et3N, 1.3 mL, 
8.5 mmol) in anhydrous THF (50 mL) was added dropwise diethylphosphorocyanidate (1.4  g, 
8.5 mmol) in 5 mL THF at 0 ℃ during a period of 10 min. The mixture was allowed to warm to 
room temperature and was stirred for an additional 12 h. Then the reaction was quenched with the 
addition of H2O (100 mL) and the mixture was extracted with ethyl acetate (2 × 100 mL). The 
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combined organic phase was dried over anhydrous Na2SO4 and evaporated under reduced pressure 
to give the crude product. The crude product was then dissolved in 25 mL THF, 50 mL H2O and 
75 mL CH3COOH, and stirred at r.t. for 4 h. Then all solvents were evaporated under reduced 
pressure to give the crude product, which was purified by column chromatography (silica gel, 
DCM: MeOH = 20:1) to give a colorless oil (952 mg, 66 % for 2 steps). 1H NMR (CD3OD): δ 
7.35 – 7.28 (m, 5H, aromatic ring), 5.08 (s, 2H, Ph-CH2-OCONH-), 4.10 – 4.06 (m, 1H, -CONH-
CH-CONH-), 3.56 – 3.55 (m, 4H, -CH2-OH), 3.21 – 3.16 (m, 4H, -CONH-CH2-), 2.27 (t, J = 7.6 
Hz, 2H, -CH2-CH2-CONH-), 2.08 – 2.03 (m, 1H, -CH-CH2-CH2CONH-), 1.92– 1.86 (m, 1H, -
CH-CH2-CH2CONH-), 1.54 – 1.53 (m, 8H, -CONHCH2-CH2CH2-CH2OH). 13C NMR (CD3OD): 
δ 174.7, 174.1, 158.3, 138.0, 129.4, 129.0, 128.8, 67.7, 62.4, 56.1, 40.2, 40.2, 38.7, 33.2, 30.8, 
30.7, 29.4, 26.8.  HRMS calcd for C21H34N3O6 [M+H]+ 424.2442, found: 424.2428. 
Cbz and acetyl group protected (S)-2-amino-N1, N5-bis(4-L-rhamnose-
butyl)pentanediamide (5). To a solution of benzyl (1,5-bis((4-hydroxybutyl)amino)-1,5-
dioxopentan-2-yl)carbamate (3, 500 mg, 1.2 mmol) and  tetra-O-acetyl-L-rhamnose (4, 1.2 g, 3.6 
mmol) in anhydrous DCM (4 mL) was added dropwise BF3/Et2O (1.3  g, 9.5 mmol) at 0 ℃ 
during a period of 10 min. The mixture was allowed to warm to room temperature and was stirred 
for an additional 48 h. Then the reaction was quenched with the addition of saturated Na2CO3 (100 
mL) and the mixture was extracted with ethyl acetate (2 × 100 mL). The combined organic phase 
was dried over anhydrous Na2SO4 and evaporated under reduced pressure to give the crude 
product, which was purified by column chromatography (silica gel, DCM: MeOH = 50:1) to give 
a white solid (305 mg, 26 %). 1H NMR (CD3OD): δ 7.38 – 7.30 (m, 5H, aromatic ring), 5.21 – 
5.09 (m, 6H, Ph-CH2-OCONH and C1-C4 proton from L-rhamnose), 5.02 – 4.97 (m, 2H, C1-C4 
proton from L-rhamnose), 4.77 – 4.75 (m, 2H, C1-C4 proton from L-rhamnose), 4.06 (t, J = 4.8 
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Hz, 1H, -CONH-CH-CONH-), 3.91– 3.84 (m, 2H, C5 proton from L-rhamnose), 3.74 – 3.68 (m, 
2H, -CH2-OH), 3.48 – 3.44 (m, 2H, -CH2-OH), 3.25 – 3.17 (m, 4H, -CONH-CH2-), 2.28 (t, J = 7.2 
Hz, 2H,-CH2-CH2-CONH-), 2.12– 1.95 (m, 20H, -OCO-CH3 and -CH-CH2-CH2CONH-), 1.64 – 
1.57 (m, 8H, -CONHCH2-CH2CH2-CH2OH), 1.18 (d, J = 6.4 Hz, 6H, Methyl group form L-
rhamnose). 13C NMR (DMSO): δ 171.4, 170.4, 169.7, 155.9, 137.0, 128.4, 127.8, 127.7, 96.6, 
70.1, 69.1, 68.7, 67.0, 67.0, 65.8, 65.4, 63.6, 54.6, 38.2, 31.9, 28.1, 26.4, 26.2, 25.8, 25.7, 20.6, 
20.5, 20.5, 17.3.  HRMS calcd for C45H66N3O20 [M+H]+ 968.4234, found: 968.4218. 
(S)-2-amino-N1,N5-bis(4-L-rhamnose-butyl)pentanediamide (6). 15 mg 10 % 
palladium on carbon (Pd/C) was added to 20 mL sealed flask under N2 protection and then a 
solution of 5 (115 mg, 0.12 mmol) in MeOH (5 mL) was added at r.t. The mixture was then 
connected to H2 balloon and stirred at r.t. for 2 h. Then the reaction mixture was filtered and the 
solvent was evaporated under reduced pressure to give the crude product, which was re-dissolved 
in 2 mL of MeOH containing MeONa (145 mg) and stirred at r.t for 3 h. The reaction mixture was 
adjusted to pH = 7 by adding ion-exchange resin (Dowex® 50WX8 hydrogen form), which was 
then filtered and evaporated to afford a crude product. This crude product was directly used for 
the next step without further purification.  
Aza-dibenzocyclooctyne conjugated L-rhamnose (DBCO-Rha). To a solution of 6 (70 
mg, 0.12 mmol) and trimethylamine (Et3N, 34 µL, 0.24 mmol) in anhydrous DMF (2 mL) was 
added DBCO-NHS (7, 48 mg, 0.12 mmol) at r.t. The mixture was stirred for 3 h. Then the solvent 
was evaporated under reduced pressure to give the crude product, which was purified by column 
chromatography (silica gel, DCM: MeOH = 10:1) to give a colorless oil (25 mg, 23 %). 1H NMR 
(CD3OD): δ 7.64 – 7.59(m, 2H, aromatic ring), 7.49 – 7.24 (m, 6H, aromatic ring), 5.15 – 5.11 (m, 
2H, C1 proton from L-rhamnose), 4.69 – 4.65 (m, 2H, Ph-CH2-NCO-), 4.21 – 4.16 (m, 1H, -
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CONH-CH-CONH-), 3.81 – 3.85 (m, 12H, C2-C5 proton from L-rhamnose and -CH2-OH), 3.21 
– 3.13 (m, 4H, -CONH-CH2-), 2.32– 1.85 (m, 8H, -CO-CH2CH2-CONH-, -CH2-CH2-CONH- and 
-CH-CH2-CH2CONH-), 1.66 – 1.52 (m, 8H, -CONHCH2-CH2CH2-CH2OH), 1.29 – 1.24 (m, 6H, 
Methyl group form L-rhamnose). HRMS calcd for C44H60N4O14Na [M+Na]+ 891.3998, found: 
891.4003. 
2.4.12   In vitro DBCO-Rha and 1, 3,4-O-Ac3ManNAz (Ac3ManNAz) activity assay 
DBCO-Rha was dissolved in MeOH to afford 10 mM stock solution; Ac3ManNAz was 
dissolved in MeOH to afford 20 mM solution. 
To 1 mL PBS was added 2.5 µL of 10 mM DBCO-Rha to afford a 25 µM solution. Then 
20 µL sample was analyzed by HPLC (column: Waters C18 3.5 µM, 4.6×100 mm, injection loop 
volume: 20 µL). The mobile phase was acetonitrile (ACN)/H2O (0-10 min: 30 %-60 % CH3CN; 
10- 20 min, 60 %-30 % CH3CN; detection wavelength: 254 nm; flow rate: 1 mL/ min).  
To 1 mL of PBS was added 2.5 µL of 10 mM DBCO-Rha solution and 12.5 µL of 20 mM 
Ac3ManNAc solution. The reaction mixture was incubated at 37 ℃ for 30 min; then 20 µL 
sample was analyzed by LC-MS using the method described above.  
2.4.13   Rha display on cell surface for flow cytometry 
Cell selective Rha display: KB, FR+ KB, HEK and MCF7 cells were seeded in 6-well 
plates, respectively, for overnight culture, then treated with 50 µM f-PEG-Mz for 48 h. Cells were 
washed three times with PBS before incubation with 50 µM of DBCO-Rha for 1 h at 37 °C. Cells 
were then washed three times with PBS, blocked with block buffer (5 % BSA in PBS), and 
incubated with 1:100 anti-rhamnose antibody (purified from human serum as described below) in 
FACS buffer (1 % BSA in PBS) for 1 h at 37 °C, and goat anti-human IgG Fc secondary antibody, 
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PE conjugated (Thermo Fisher Scientific) in FACS buffer for 1 h at 37 °C. Cells were then washed 
three times with PBS before being subjected to flow cytometry. 
Concentration dependent Rha display: The procedures were same as described above 
except the concentration of f-PEG-Mz treatment. For the concentration-dependent Rha display 
assay, FR+ KB cells were treated with 0 µM, 12 µM, 50 µM, 100 µM f-PEG-Mz for 48 h. 
2.4.14   Anti-Rha antibody purification and ELISA detection 
Anti-Rha antibody purification and ELISA titration assay were done as previously 
described.99 The Rha-coupled sepharose beads were equilibrated with PBS (pH 7.4) and then 
incubated with human serum at 4 °C overnight. The beads were then washed with PBS and eluted 
with elution buffer (0.2 M glycine, pH 2.5). The elution was neutralized with 1 M Tris-HCl (pH 
9.0) and concentrated with PBS using 10 kDa centrifugal filter (Millipore).  
The 96-well ELISA plates were coated with 5 µg/mL Rha conjugated BSA in PBS at 4 °C 
overnight. The plates were washed with PBS containing 0.5 % (v/v) Tween 20 (PBST) and then 
blocked with 5 % (w/v) BSA in PBST for 2 h. The plates were washed with PBS and incubated 
with anti-Rha antibodies at various dilutions in PBST for 2 h at RT. The plates were washed, 
followed by incubation with goat anti-human IgG Fc highly cross-adsorbed secondary antibody, 
HRP conjugated (Thermo Fisher Scientific) for 1 h at RT. After plates washing, enzyme substrate 
tetramethylbenzidine (TMB, Sigma) was added and incubated for 15 min before 1 M HCl addition. 
The absorbance was measured at OD450 on a microplate reader.  
2.4.15   The complement supplementary assay and complement-dependent 
cytotoxicity (CDC) assay 
FR+ KB cells were incubated with 50 µM Ac4ManNAz for 48 h, and then washed and 
labeled by 50 µM DBCO-Rha for 2 h. Subsequently, one group were treated with 20 % human 
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serum and 4 µL 1 % (v/v) human complement (Sigma, 46 units/mL for 5 x 108 cells) for 4 h at 37 
°C; and the other group was treated with 20 % human serum without extra complement for 4 h at 
37 °C. Cell viability was then determined by CCK-8. In a parallel study, FR+ KB cells were 
incubated with 50 µM Ac4ManNAc for 48 h, and then washed and labeled by 50 µM DBCO-Rha 
for 2 h. Subsequently, cells were treated with 20 % human serum and 4 µL 1 % (v/v) human 
complement for 4 h at 37 °C. This group served as a negative control where Rha wasn’t displayed 
on the cell surface. 
KB, FR+ KB, HEK and MCF7 cells were seeded in 6-well plates, respectively, for 
overnight culture. Cells were then treated with 50 µM f-PEG-Mz, or 50 µM Ac4ManNAc, or 50 
µM Ac4ManNAz for 48 h at 37 °C. Cells were washed three times with PBS and then incubated 
with 20 % (v/v) human serum and 4 µL 1% (v/v) human complement (Sigma, 46 units/mL for 5 x 
108 cells) for 4 h. Subsequently, 10 % (v/v) CCK-8 was added, and the plates were further 
incubated at 37 °C for 3 h. The plates were then read at OD450 on Microplate Reader. 
2.4.16   Macrophage activation and ADCP detection 
THP-1 cells were differentiated and induced using 100 ng/mL of phorbol 12-myristate 13-
acetate (PMA, Abcam) for 48 h. Then THP-1 cells were stained with Vybrant DiD Cell-Labeling 
Solution (Thermo Fisher Scientific) at RT for 20 min. 
The FR+ KB cells were cultured with 50 µM f-PEG-Mz, 50 µM f-PEG, or 50 µM 
Ac3ManNAz, respectively, in RPMI 1640, folic acid-depleted medium for 48 h. Then the cells 
were washed three times and clicked with DBCO-Rha (or without DBCO-Rha for controls) for 1 
h. Cells were washed for three times with PBS and re-suspended in RPMI 1640, no folic acid 
medium supplemented with anti-Rha antibodies (1:100 dilutions, final concentration= 5 µg/mL) 
for 2 h. Then cells were washed and stained with Vybrant DiO Cell-Labeling Solution (Thermo 
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Fisher Scientific) at RT for 20 min. The stained FR+ KB cells were mixed with DiD stained, PMA 
activated THP-1 cells (describe above, 2 x 105 cells) at 1:1 ratio for 3 h at 37 °C. Phagocytosis was 
analyzed by flow cytometry. The % phagocytosis was calculated as the percentage of dual color 
labeled cells. For confocal fluorescence microscopy imaging, the mixed cells were fixed on the 
slides with 4 % paraformaldehyde solution after applying the fluoroshield mounting medium with 
DAPI.  
2.5   Conclusion and significance 
In conclusion, we have described a novel strategy to redirect or enhance immune-mediated 
killing towards otherwise immune inert targets. The same strategy should be applicable to targeting 
other types of cancer cells or various bacteria. ManNAz was used as azido carbohydrate to serve 
an anchor on the target surface in the current stage. However, other azido carbohydrates or even 
multi-azido carbohydrates can be used to increase the number of azido group, and thus the ARM 
displayed on the surface. In this study, we used f-PEG-Mz to achieve selective destruction of FR 
overexpressing cells as a demonstration of feasibility. Other delivery methods of azido sugars can 
also be used to target different cell-surface biomarkers. 68, 104 Other antibody recruiting moieties 
can also be used besides Rha.  The antibody recruiting moiety covalently binds to the glycan on 
the surface of targets, is stable, and ensures the long-lasting effect.  One factor that can affect the 
efficacy of this immune therapy strategy is the antibody abundance variations among individuals. 
However, anti-Rha antibody generally is among those with the highest abundance.84, 91, 105 
Nevertheless, future work is needed to decipher the relationship between the abundance of the 
anti-carbohydrate antibodies and the efficacy of this immune therapy under different physiological 
and pathological conditions. This novel strategy can serve as research tools to study immune 
responses and therapeutic agents for developing immune therapies. 
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3   GENETIC ENCODING UNNATURAL AMINO ACIDS (UAAS) INTO PROTEINS 
FOR CAPTURING CARBOHYDRATE-PROTEIN INTERACTIONS 
3.1   Introduction 
3.1.1  Genetic code expansion strategy 
Protein translation happens in ribosome. Basically, aminoacyl-tRNA synthetases catalyze 
the linkage of the appropriate amino acid to its tRNA to form aminoacyl-tRNA. Each amino acid 
was added to the growing end of a polypeptide chain acheived by complementary base pairing 
between the anticodon on its attached tRNA and the codon on mRNA (Figure 3.1).106 
 
Figure 3.1 The synthesis of aminoacyl-tRNA with aminoacyl-tRNA synthetase. 
 
With rare exceptions, all living organisms preserve a universal genetic code including 61 
codons for 20 amino acids translation and other 3 codons for the termination of protein translation. 
Genetic code has been expanded to encode unnatural amino acids (UAAs) via introduced 
orthogonal tRNA/ aminoacyl-tRNA synthetase (aaRS) pair in prokaryotes and eukaryotes hosts 
which endow proteins with novel functionalities (Fig 3.2).107 The orthogonal set for genetic code 
expansion includes a unique anticodon, orthogonal tRNA, orthogonal aaRS and unnatural amino 
acid. The orthogonal set was required not to be recognized by endogenous tRNA/ aaRS pair, and 

































Figure 3.2 Machinery of genetic code expansion. 
Genetic code has been expanded to encode unnatural amino acids via introduced 
orthogonal tRNA/ aminoacyl-tRNA synthetase (aaRS) pair with unnatural amino acids. 
(modified from Wang, Qian, Angela R. Parrish, and Lei Wang. "Expanding the genetic code for 
biological studies." Chemistry & biology 16.3 (2009): 323-336.) 
 
Three major types of orthogonal tRNA/aaRS pairs are commonly used for the incorporation 
of UAAs in different hosts including M. jannaschii tRNACUA
Tyr /TyrRS, E.coli tRNACUA
Tyr /TyrRS 
and tRNACUA
Pyl /PylRS pair from M. mazei or M. barkeri. The orthogonal M. jannaschii 
tRNACUA
Tyr /TyrRS was first reported and used in E.coli in 2000.109 It was orthogonal to E.coli host, 
but not in eukaryotes. E.coli tRNACUA
Tyr /TyrRS was first applied to genetic code expansion in 
mammalian cells in 2003.110 E.coli tRNACUA
Tyr /TyrRS pair had a high efficiency in mammalian 
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cells, but the synthetase evolution was done in yeast which was troublesome to handle. The 
tRNAPyl/PylRS pair was first reported as a genetic code expansion tool in E. coli in 2004,111 since 
then, the PylRS mutants have been used to site specifically incorporate UAAs in response to UAG 
codon in prokaryotes and even eukaryotes. The major advantage to use M. barkeri or M. mazei 
tRNACUA
Pyl /PylRS orthogonal pair is that they have negligible cross-reactivity with other aaRSs or 
tRNAs. That means, the newly evoluted synthetase for a uaa in E. coli can be directly applied to 
eukaryotic cells without further evolution since it is both orthogonal in prokaryotic and eukaryotic 
cells. 
3.1.2  Genetically encoded crosslinker to study molecular interactions 
Biological functions are carried out by molecular interactions. However, limited strategies 
are available to understand the process, such as when and where the interactions happen. The 
genetically encoded crosslinking UAAs provide the tool to capture the weak and transient 
molecular interactions in living system. Two types of crosslinking UAAs have been developed. 
Photocrosslinking UAAs, including the p-benzoyl-L-phenylalanine (Bpa), p-azido-L-
phenylalanine (AzF) and others, are able to form covalent bond with nearby molecules upon UV 
treatment with high efficiency (Fig 3.3 A).112-113 Proximity-based chemical crosslinking UAAs 
normally bear electrophilic moieties which can react with nucleophilic amino acid upon complex 
and bind in a proximity-based manner, providing the specificity to capture molecular interactions. 
Several proximity-based chemical crosslinking UAAs have been developed targeting different 
natural amino acid including cysteine, histidine, lysine, glutamic acid and tyrosine.114-120 O-(3-
Chloropropyl)-L-tyrosine (CprY, Fig 3.3 B) can form a covalent thioether bond with cysteine 
residues in a close proximity.115 Fluorosulfate-L- tyrosine (FSY) was recently developed to 
selectively react with proximal lysine, histidine, and tyrosine via SuFEx when incorporated onto 
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proteins.119 The resulting covalent crosslinking between FSY incorporated protein and its 
interacting proteins can be directly mapped via mass spectrometry in vitro and also in vivo. Overall, 
the genetically encoded crosslinking UAAs empowers proteins with new functionality to form 
covalent bond with molecules nearby, providing the novel strategy to capture molecular 
interactions in a covalent state.  
 
Figure 3.3 The structures of partial incorporated UAAs for protein crosslinking. 
 
3.1.3  Carbohydrate-protein interactions  
Among the molecular interactions, carbohydrate-protein interactions play important biological 
roles in living systems. Interactions between carbohydrates and proteins occur through glycoproteins, 
glycolipids and polysaccharides presented on the cell surface. The interactions are typically weak with rare 
exceptions.121-122 Multivalent carbohydrate ligand polymer could somehow overcome the limitation to 
increase the binding affinities, however, it suffered from chemical synthesis of those multivalent 
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hydrophobic packing, and metal coordination.126 Hydrogen bonds between sugar hydroxyl groups and 
carbonyl or NH groups on protein backbone are commonly observed. Ionic interactions are found in the 
complexation of proteins with negatively charged sugars, such as sialic acids, phosphorylated or sulfated 
sugars. Tryptophan on proteins was observed in most crystal structures to form the hydrophobic packing 
against sugar.  
Carbohydrate-protein interactions are involved in various biology processes, including cell 
adhesion, tumor cell metastasis and also bacteria and virus invasion.127 Due to the essential roles of 
carbohydrate-protein interactions, strategies to study the interactions have also been developed. One 
method is using high-throughput carbohydrate microarray to probe these carbohydrate-protein interactions. 
Displaying various carbohydrates on a chip surface will allow mapping the carbohydrate-protein 
interactions in a high-throughput manner via incubation with interested proteins.128 The carbohydrate 
microarray has been a convenient tool for screening glycan binding proteins (GBPs), and also exploring 
their binding preference. After which, numerous plant lectins, glycan antibodies, virus, and microbial toxins 
have been analyzed for their binding specificity on carbohydrate microarray.129 The other tool to study 
carbohydrate-protein interactions is bioengineering cell surface glycans with functional groups. Taking 
advantage of metabolic glycan labeling, a sialic acid analog with a photoreactive aryl azide moiety has been 
displayed on the B cell surface. Upon UV light activation, sialic acid bearing the aryl azide moiety crosslink 
with B cell CD22 in a cis interaction, resulting in formation of its homomultimers.123 Though several 
strategies have been developed and optimized, major challenges still remain to uncover the carbohydrate-
protein interactions. More diverse and elegant methods are urgently need for better understanding the 
carbohydrate-protein interactions and their downstream biological processes. 
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3.1.4  Siglec-7 interactions with carbohydrate 
 
Figure 3.4 Siglec-7 domains and its preferred binding ligand. 
 
Siglec-7 was mainly expressed on natural killer (NK)-cell surface as an inhibitory 
receptor.130 Siglec-7 interacts with sialic acid in cis on the same cell surface or trans interactions 
between cells, leading to downstream immune inhibitory signaling.131 Thus, highly sialylated 
pathogens were able to interact with siglecs to inhibit host immune system, which would contribute 
to pathogenicity and pathogens survival within host.132-133 Due to the important roles of siglec-7 
in the biological processes, we choose siglec-7 as our target for proof-of-principle study. 
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Figure 3.5 sigelc-7 domains and crystal structures (PDB 2HRL). 
(A) Structure of sugar ligand. (B) The orientation of sugar ligand in the crystal structure. 
(C) Co-crystallization of GT1b with siglec-7, key residues were shown in yellow sticks. (D) 
close-up view of the key interactions between terminal Neu5Ac and Arg124 on siglec-7. 
 
Siglec-7 is a transmembrane protein containing five domains, a V-set immunoglobulin 
domain which is also the sialic acid binding domain, and two C2-set immunoglobulin domains in 
the extracellular region, and two immunoreceptor tyrosine-based inhibition motif (ITIM) like 
domains at the N-terminus in cytoplasm (Fig 3.4 A).132 The preferred carbohydrate ligand for 
siglec-7 binding is Neu5Acα2–8Neu5Ac-containing glycans (Fig 3.4 B, Neu5Ac is one of the 






































crystallization of siglec-7 and carbohydrate ligand provided insights into the structural basis of 
binding specificity.135-136 Siglec-7 co-crystallized with GT1b analog (Fig 3.5 A) providing  direct 
information that GT1b had numbers contacts with siglec-7, including ten direct hydrogen bonds, 
seven water-mediated hydrogen bonds and a number of hydrophobic interactions.135 The sugar 
ligand is in a bent conformation (Fig 3.5 B). The reducing end glucose interacted with siglec-7 
W74 residue, and a hydrogen bond formed between the sugar C6 hydroxyl and head group amide 
of N133. Those interactions contribute to anchoring the glycan reducing end facing into the siglec-
7 binding pocket (Fig 3.5 C).135-136 The sub-terminal Neu5Ac and the branch-point galactose made 
rare direct interactions with protein. The terminal Neu5Ac and the glucose in the reducing end are 
in a closest position with 3.8 A which may supported by the interactions with siglec-7 and also the 
intramolecular hydrogen bonds.135 The terminal Neu5Ac had a key interactions for the ligand 
binding to siglec-7: salt bridge between the carboxylate on Neu5Ac and the guanidinium group of 
R124 on siglec-7 protein (Fig 3.5 D). After understanding the structural determination of siglec-7 
binding with sugar ligand, we choose Y9 as the target residue to incorporate crosslinker into siglec-
7 proteins via genetic code expansion strategy. Locating near the binding pocket, Y9 on siglec-7 
have rare interactions with substrate binding, and it’s in a closest distance with the terminal sialic 
acid.  
3.2   Objectives and general scheme 
Carbohydrate-protein interactions are essential for body function but difficult to capture 
and identify. Expanding the genetic code to incorporate crosslinkers into proteins enables us 
capture and identify unknown glycoproteins and manipulate carbohydrate-protein interactions. As 
a proof-of-principle study, we initially focus on the locking of protein with sugar ligands in vitro 
via chemical crosslinking or photo activated crosslinking in a proximity-based manner. The protein 
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target, siglec-7, was purified and refolded from E.coli, together with UAAs incorporated siglec-7 
proteins. Functional assay on carbohydrate microarray has been conducted to ensure the binding 
activity of siglec-7 and UAAs incorporated siglec-7. Tetrasaccharide containing Neu5Acα2–
8Neu5Ac- glycans and SH modified tetrasaccharide are under synthesis which act as the binding 
ligand to UAAs incorporated siglec-7 proteins. Achieving the crosslinking of carbohydrate-protein 
interactions in vitro, more efforts will be continuously made for in vivo study which will be benefit 
for identifying unknown glycoproteins and understanding downstream glycan-related biological 
processes. 
3.3   Results and discussion 
3.3.1  Sigelc-7 V set domain protein expression, purification and refolding 
The gene of sigelc-7 V set domain (the siglec-7 mentioned below was the V set domain, 
except specially notified) was constructed into pBAD vector with His6 tag at the C terminal. The 
outer membrane V set domain siglec-7 was expressed in Escherichia coli (E. coli) by 0.2% 
arabinose followed by incubation at 25 °C for 20 h with vigorous shaking (200 rpm).  The siglec-
7 was purified from inclusion body with 8M urea with the yield of 20 mg/ L culture. 0.5 µg and 3 
µg protein was loaded for SDS-PAGE. The result showed high purity of the siglec-7 proteins, and 
the molecular weight was well correlated with the protein size (Fig 3.6 A). Step-wise dialysis 
strategy with gradient decreased concentrations of urea was used to refold the denatured protein 
and retain its binding activities.137 Siglec-7 proteins was finally concentrated in PBS buffer, and 
the intact protein mass was analyzed with electrospray ionization time-of-flight mass spectrometry 




Figure 3.6 Characterization of widetype siglec-7 protein. 
(A) SDS-PAGE of purified widetype siglec-7 proteins with 0.5 µg and 3 µg loading 
amound. (B) ESI-TOF MS analysis of intact siglec-7 protein mass. 
 
3.3.2  Characterization and functional analysis of siglec-7 protein 
The purified and refolded siglec-7 was characterized by circular dichroism (CD) and 
glycan microarray assay to ensure the binding activity. 0.1 mM siglec-7 protein was subjected to 
CD measurement on a Jasco J-810 spectropolarimeter at 277 K using a 0.005 cm cuvette. The 
spectrum was recorded in the range of 250 nm to 200 nm at a scan rate of 50 nm min-1 with a 
bandwidth of 1 nm. Analysis of the CD spectrum indicated that siglec-7 was folded and composed 
of β-strands as the major secondary-structure elements which consistent with the siglec-7 tertiary 







repeats of each glycan epitope) was used for functional analysis of refolded siglec-7. After 
incubation the protein with microarray for 2 h, His6 antibodies conjugated Alexa 647 were applied 
to the array slide. The array was scanned with GenePix 4000B microarray scanner at 635nm 
wavelength (Fig 3.7 B). The microarray was analysized according to the fluorescence intensity, 
and data was interpreted into a two-dimensional bar chart. The y-axis is the fluorescence intensity 
to reveal relative protein binding signals for each glycan (Fig 3.7 C). The glycan ligands with 
incredible signals were pointed out which indicated that the siglec-7 refolded properly to bind only 
with the glycan ligands containing 2,8-linked sialic acid-containing glycans, not bind with other 
glycan ligands without sialic acid (Fig 3.8 D). 
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Figure 3.7 Characterization the function of refolded siglec-7. 
(A) Circular dichroism (CD) diagram of refolded siglec-7 protein. siglec-7 was folded and 
majorly composed of β-strands. (B) Glycan microarray fluorescence image using GenePix 4000B 
microarray scanner at 635nm wavelength. (C) Microarray analysis according to the fluorescence 
intensity. The microarray was analysized according to the fluorescence intensity, and data was 
interpreted into a two-dimensional bar chart. (D) The glycan structures showed incredible binding 
activity towards refolded siglec-7 protein. 
 



















































































3.3.3  Incorporate unnatural amino acid (UAAs) into  siglec-7 protein 
The unnatual amino acids (UAAs), BprY, CprY, have been reported to incorporate on 
certain proteins expressed by E. coli.138 To verify UAAs incorporation in siglec-7, we expressed 
the siglec-7 gene containing a TAG codon at position 9 together with the tRNACUA
Pyl /BprYRS pair 
or tRNACUA
Pyl /CprYRS pair in E.coli. The protein was refolded as the widetype siglec-7 described 
above. As shown in Figure 3.8 A, in the absence of BprY or CprY, no full-length SIGLEC-7 was 
detected; when 0.5 mM of BprY or CprY was added in growth medium, full-length sigelc-7 was 
expressed and purified. The intact protein mass of siglec-7 (9BprY) or sigelc-7 (9CprY) were 
analyzed with electrospray ionization time-of-flight mass spectrometry (ESI-TOF MS), which 
confirmed the successful incorporation of BprY or CprY (Fig 3.8 B). 
 
Figure 3.8 Incorporation of unnatural amino acids into siglec-7 protein. 
(A) SDS-PAGE showed the protein expression with or without unnatural amino acid. C: 
CprY; B: BprY. (B) The ESI-TOF MS of CprY incorporated protein intact mass. 
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3.3.4  Chemoenzymatic synthesis of thiol modified tetrasaccharide  
Compound 1 and compound 2 was synthesized according published paper.139-140 
Compound 5 was synthesized via enzymatic catalysis with compound 1 and 4 in the presence of 
aldolase, CMP-sialic acid synthetase and α-2,8 sialic acid transferase (Fig 3.9). Final product 6 
was under synthesis. 
 
Figure 3.9 Synthesis scheme for thiol modified tetrasaccharide. 
 
3.4   Materials and general methods 
3.4.1  Primers used 






















































































α-2,8 sialic acid transferase
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Siglec-7 HindIII Rev: 
GTTGTTAAGCTTTTAGTGATGGTGATGGTGATGGTGGGTCAAGGCGGTAACATTAAC
ACT 
Siglec7-Y9TAG Nde1 For: 
GGTGGTCATATGCAGAAAAGTAATCGTAAAGATTAGAGCCTGACCATGCAGAGC 
3.4.2  Molecular cloning 
Siglec-7 gene was synthesized and purified as fragment from GENEWIZ. Primers were 
synthesized and purified by Integrated DNA Technologies (IDT). All molecular biology reagents 
were obtained from New England Biolabs. 









pBAD Siglec-7 plasmid: 
Primers siglec-7 NdeI For and siglec-7 HindIII Rev were used to create siglec-7 in pBAD 





pBAD Siglec-7 (Y9TAG) plasmid: 
Primers siglec-7(Y9TAG) NdeI For and siglec-7 HindIII Rev were used to create siglec-7 




(X: amber codon TAG at 9th position) 
3.4.3  Siglec-7 protein expression and purification 
pBAD siglec-7 was transformed into DH10B and plated on LB argar plate supplemented 
with 100 µg/mL ampicillin (Amp). Single colony was picked from the transformed plate for 
overnight growing in 5 mL 2X YT (5 g/L NaCI, 16 g/L Tryptone, 10 g/L Yeast extract) at 37 °C, 
200 rpm with antibiotics. The culture was 1:100 diluted in 200ml 2X YT and grown to an OD 0.5 
with antibiotic selection. Then the medium was added with 0.2% L-Arabinose, and the expression 
wascarried out at 25 °C, 200 rpm for 18 hr. The cells were harvested at 8000 g, 4 °C for 10 min. 
For protein purification, the cell pellet was resuspended with 15 mL cold lysis buffer (20 mM 
sodium phosphate, 200 mM NaCI, 20 mM imidazole, pH 7.5) supplemented with EDTA free 
protease inhibitor cocktail, 1 mg/mL lysozyme, 1 µg/mL DNase. The cells then were lysised by 
sonification, after which the cell lysis solution was centrifuged at 20,000 g at 4 °C for 10 min, the 
supernatant was discarded. The pellet was resuspended in 8 mL cold suspension buffer （20 mM 
sodium phosphate, 200 mM NaCI, 20 mM imidazole, 8M urea, pH 7.5）, and mixed at 4 °C for 
30 min. The resuspension solution was centrifuged at 20,000 g at 4 °C for 10 min, and the 
supernatant was collected and incubated with 500 µL Ni Affinity resin at 4 °C for 1 hr. The resin 
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was transferred into a Pierce™ Centrifuge Columns (ThermoFisher Scientific). After 2 times wash 
with 10 mL suspension buffer, the protein was eluted with  5 mL elution buffer (20 mM sodium 
phosphate, 200 mM NaCI, 300 mM imidazole, 8M urea, pH 7.5). The yield for siglec-7 after 
purification with Ni-NTA resin is around 30 mg/L.  
3.4.4  Protein refolding 
The siglec-7, siglec-7(Y9BprY) or siglec-7 (Y9CprY) proteins were diluted into 0.1 
mg/mL with elution buffer and dialyzed against gradient urea buffer (20mM sodium phosphate, 
200 mM NaCI, X M urea, pH 7.5, which X represents 6, 4, 2 and 0) for 6h at 4 °C. The refolded 
protein was concentrated with 10 kDa Amicon centrifugal filter unit. 
3.4.5  Incorporation of UAAs into siglec-7 (Y9TAG) 
For the incorporation of BprY or CprY into siglec-7, the plasmid pBAD siglec-7 (Y9TAG) 
was co-transformed with pEVOL-BprYRS or pEVOL-CprYRS into DH10B, and plated on LB 
argar plate supplemented with 100 µg/mL ampicillin (Amp) and 34 µg/mL chloramphenicol (Cm). 
Single colony was picked from the transformed plate for overnight growing in 5 mL 2X YT at 37 
°C, 200 rpm with antibiotics. The culture was 1:100 diluted in 200ml 2X YT and grown to an OD 
0.5 with antibiotic selection. Then the medium was added with 0.2% L-Arabinose plus 0.5 mM 
BprY or CprY, and the expression was carried out at 25 °C, 200 rpm for 18 hr. The protein 
purification was carried out as described above. The yield for siglec-7 (Y9BprY) or siglec-7 
(Y9CprY) after purification with Ni-NTA resin is around 10 mg/L. 
3.4.6  Glycan microarray  
The glycan microarray was blocked with BE buffer (50 mM ethanolamine in 50 mM 
sodium borate buffer pH 9.2) at RT for 1 h. After washing three times with TSMTB buffer (20 
mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2, 0.05 % Tween-20, 1 % BSA), 
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protein samples were applied to the array and incubated at RT for 1 h. Samples were removed 
and washed with TSMT buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM CaCl2, 2 mM 
MgCl2, 0.05 % Tween-20) for three times, then His6 antibody conjugated AlexaFluor 647 was 
applied to detect siglec-7 binding at RT for 1 h. After which, the array was washed with TSMT 
buffer, TSM buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2) and 
water for three times sequentially. The array was finally sake in water jar for 5 min, and air dried 
before fluorescence detection on GenePix 4000B scanner at 635nm. The list of glycan 
identification is attached in Appendix E. 
3.5   Conclusion and significance 
Although carbohydrate-protein interactions were vital important, less studies were carried out 
on these interactions because of the low binding affinities. In this study, we aim to develop a novel 
method to lock the carbohydrate-protein interactions in covalent bonding with the strategy of 
genetic code expansion. As a proof-of-principle study, the study was initially carried out on the 
locking of protein with sugar ligands in in vitro via proximity-based chemical crosslinking. This 
method has the potential to use in vivo to manipulate the carbohydrate-protein interactions on 
specific desired protein, to capture and identify unknown glycoproteins, and to investigate its 
downstream biological signaling.  
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4   SIGNIFICANC AND FUTURE OUTLOOK 
O-GlcNAcylation is essential for multiple cellular signaling cascades, including gene 
transcription, protein translation, cell cycle, and nutrient sensing. By affecting the protein stability, 
activity, or affecting protein phosphorylation status, O-GlcNAcylation is involved in the diseases 
development such as diabetes, Alzheimer’s disease, and cancer development. Because of the 
importance of O-GlcNAc and its crucial role in disease pathology, the enzymes controlling O-
GlcNAcylation levels are considered as therapeutic targets. Substrate promiscuity of OGT and 
OGA has been shown to be valuable for enzymatic catalysis and O-GlcNAcylation level control. 
However, partly because of the difficulties in obtaining glycopeptides with modified GlcNAc 
residues, structure determination during GlcNAc-recognition by hOGA remains unclear. In the 
first chapter, glycopeptides containing different GlcNAc derivatives were successfully synthesized 
to study the OGA substrate promiscuity towards GlcNAc recognition. hOGA was less 
promiscuous in tolerating glycopeptide substrates with modified GlcNAc, and changes in the C2, 
C4, and C6 positions of GlcNAc partially affected its recognition. Interestingly, we found that 
OGT and OGA possessed different levels of tolerance to the same sugar moiety, such as GlcNPh, 
GlcNTFA, and 4-OMe-GlcNAc. Therefore, the acquired GlcNAc derivatives, which were well-
recognized by OGT but not hydrolyzed by OGA, were called potential OGA-resistant O-
GlcNAcylation probes. Those probes may increase the O-GlcNAcylation level in vivo when the 
peracetylated compound is metabolically incorporated. O-GlcNAcylation is dynamic and 
reversible process, providing the difficulties identifying O-GlcNAcylated proteins. With the OGA-
resistant O-GlcNAcylation probes, more O-GlcNAcylated proteins can be identified which may 
play important roles in the cellular signaling transduction, and become promising targets for 
disease and cancer treatment. Indeed, our group have further developed one the GlcNAc 
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derivatives, peracetylated 4-deoxy-N-azidoacetylglucosamine (Ac3-4-deoxy-GlcNAz) as the 
OGA-resistant probe. 4-deoxy-GlcNAz modification was resistant to the hydrolysis of OGA, 
providing a greater potency for labeling. Combined with click chemistry, this probe can be used 
in a variety of applications, including direct live cell imaging, affinity enrichment, and proteomics, 
all of which will accelerate the discovery of new O-GlcNAc modified proteins and provide insights 
into the function of O-GlcNAcylation. 
Installation of an antibody-recruiting moiety on the surface of disease-relevant cells can lead 
to the selective destruction of targets by the immune system. Such an approach can be an 
alternative strategy to traditional chemotherapeutics in cancer therapy and possibly other diseases. 
In the second chapter, we describe the development of a new strategy to selectively label targets 
with an antibody-recruiting moiety through its covalent and stable installation, complementing 
existing methods of employing reversible binding. This is achieved through selective delivery of 
1,3,4-O-acetyl-N- azidoacetylmannosamine (Ac3ManNAz) to folate receptor- overexpressing 
cells using an folate-PEG (polyethylene glycol)- Ac3ManNAz (f-PEG-Mz) via a cleavable linker. 
As such, Ac3ManNAz is converted to cell surface glycan bearing an azido group, which serves as 
an anchor to introduce L-rhamnose (Rha), a hapten, via a click reaction with aza-
dibenzocyclooctyne (DBCO)-Rha. We tested this method in several cell lines including KB, HEK-
293, and MCF7 and were able to demonstrate the following: 1) Rha can be selectively installed to 
the folate receptor overexpressing cell surface and 2) the Rha installed on the target surface can 
recruit anti-rhamnose (anti-Rha) antibodies, leading to the destruction of target cells via 
complement-dependent cytotoxicity (CDC) and antibody- dependent cellular phagocytosis 
(ADCP).  
106 
The same strategy should be applicable to targeting other types of cancer cells or various 
bacteria. ManNAz was used as an azido carbohydrate to serve as an anchor on the target surface 
in the current stage. However, other azido carbohydrates or even multiazido carbohydrates can be 
used to increase the number of azido groups and thus the ARM displayed on the surface. In this 
study, we used f-PEG-Mz to achieve selective destruction of FR overexpressing cells as a 
demonstration of feasibility. Other delivery methods of azido sugars can also be used to target 
different cell-surface biomarkers. Other antibody recruiting moieties can also be used besides Rha. 
The antibody recruiting moiety covalently binds to the glycan on the surface of targets, is stable, 
and ensures the long-lasting effect. One factor that can affect the efficacy of this immune therapy 
strategy is the antibody abundance variations among individuals. However, anti-Rha antibody 
generally is among those with the highest abundance. Nevertheless, future work is needed to 
decipher the relationship between the abundance of the anticarbohydrate antibodies and the 
efficacy of this immune therapy under different physiological and pathological conditions. This 
novel strategy can serve as a research tool to study immune responses and therapeutic agents for 
developing immune therapies. 
Carbohydrate-protein interactions are essential for body function, but implicated to capture 
and identify. Expanding the genetic code to incorporate crosslinkers into proteins enables us 
capture and identify unknown glycoproteins, and manipulate carohydrate-protein interactions. The 
genetically encoded crosslinking UAAs include photocrosslinker and chemical crosslinker. 
Problems of the photocrosslinking reaction may exist. First, after irradiation, the formed highly 
reactive species can unspecifically react with C-H bonds on the nerghbouring moleculs. Second, 
the irradiation generated intermediates are easily quenched in the solution. That suggest the 
photocrosslinking approach is of low selectivity and efficiency which may not suitable for 
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enriching and stabilizing the weak and transient molecular interactions. Chemical crosslinkers 
usually bear electrophilic moieties that can react with nucleophilic amino acids on the interacting 
molecules in a proximity based reactivity. Upon complex approaching or binding, the local 
concentrations of the reactants increase and the reaction can happen to from the covalent bonds. 
The reaction can not happen without the proximity based concentration effect. The genetically 
encoded chemical crosslinkers have emerged as powerful tool for capturing the weak and transient 
protein interactions in living cells. Thus, in this chapter, we finally decided the usage of genetically 
encoded chemical crosslinking UAAs as the tool to capture the weak carbohydrate-protein 
interactions. Other factors need to be further considered, including the positions to incorporate the 




















































































































Appendix E The glycan identification list on microarray 
G1      Neu5Acα2–3Galβ1–4Glc     
G2      Neu5Gcα2–3Galβ1–4Glc     
G3      Kdnα2–3Galβ1–4Glc     
G4      Neu5Ac8Meα2–3Galβ1–4Glc     
G5      Neu5Acα2–3(GalNAcβ1–4)Galβ1–4Glc     
G6      Neu5Gcα2–3(GalNAcβ1–4)Galβ1–4Glc     
G7      Kdnα2–3(GalNAcβ1–4)Galβ1–4Glc     
G8      Neu5Acα2–3(Galβ1–3GalNAcβ1–4)Galβ1–4Glc     
G9      Neu5Gcα2–3(Galβ1–3GalNAcβ1–4)Galβ1–4Glc     
G10      Kdnα2–3(Galβ1–3GalNAcβ1–4)Galβ1–4Glc     
G11      Neu5Acα2–8Neu5Acα2–3Galβ1–4Glc     
G12      Neu5Acα2–8Neu5Gcα2–3Galβ1–4Glc     
G13      Neu5Acα2–8Kdncα2–3Galβ1–4Glc     
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G14      Neu5Gcα2–8Neu5Acα2–3Galβ1–4Glc     
G15      Neu5Gcα2–8Neu5Gcα2–3Galβ1–4Glc     
G16      Kdnα2–8Neu5Acα2–3Galβ1–4Glc     
G17      Kdnα2–8Neu5Gcα2–3Galβ1–4Glc     
G18      Kdnα2–8Kdnα2–3Galβ1–4Glc     
G19      Neu5Acα2–8Neu5Acα2–3(GalNAcβ1–4)Galβ1–4Glc     
G20      Neu5Acα2–8Neu5Gcα2–3(GalNAcβ1–4)Galβ1–4Glc     
G21      Neu5Gcα2–8Neu5Acα2–3(GalNAcβ1–4)Galβ1–4Glc     
G22      Neu5Gcα2–8Neu5Gcα2–3(GalNAcβ1–4)Galβ1–4Glc     
G23      Kdnα2–8Neu5Acα2–3(GalNAcβ1–4)Galβ1–4Glc     
G24      Kdnα2–8Neu5Gcα2–3(GalNAcβ1–4)Galβ1–4Glc     
G25      Kdnα2–8Kdnα2–3(GalNAcβ1–4)Galβ1–4Glc     
G26      Neu5Acα2–3Galβ1–3GalNAcb1–4(Neu5Aca2–3)Galβ1–4Glc     
G27      Neu5Acα2–8Neu5Acα2–3(Galβ1–3GalNAcβ1–4)Galβ1–4Glc     
G28      Neu5Gcα2–8Neu5Gcα2–3(Galβ1–3GalNAcβ1–4)Galβ1–4Glc     
G29      Kdnα2–8Neu5Gcα2–3(Galβ1–3GalNAcβ1–4)Galβ1–4Glc     
G30      Neu5Acα2–8Neu5Acα2–3Galβ1–3GalNAcβ1–4(Neu5Aca2–3)Galβ1–4Glc     
G31      GalNAcβ1-­4(Neu5Acα2–8Neu5Acα2–8Neu5Acα2–3)Galβ1–4Glc     
G32      Neu5Acα2–8Neu5Acα2–8Neu5Acα2–3Galβ1–4Glc     
G33      GlcNAcβ1–3Galβ1–4Glc     
G34      Galβ1–3GlcNAcβ1–3Galβ1–4Glc     
G35      Galβ1–4GlcNAcβ1–3Galβ1–4Glc     
G36      Galβ1–4(Fucα1–3)GlcNAcβ1–3Galβ1–4Glc     
G37      Neu5Acα2–3Galβ1–4GlcNAcβ1–3Galβ1–4Glc     
G38      Neu5Gcα2–3Galβ1–4GlcNAcβ1–3Galβ1–4Glc     
G39      Kdnα2–3Galβ1–4GlcNAcβ1–3Galβ1–4Glc     
G40      Neu5Ac8Meα2–3Galβ1–4GlcNAcβ1–3Galβ1–4Glc     
G41      Neu5Acα2–3Galβ1–3GlcNAcβ1–3Galβ1–4Glc     
G42      Neu5Gcα2–3Galβ1–3GlcNAcβ1–3Galβ1–4Glc     
G43      Kdnα2–3Galβ1–3GlcNAcβ1–3Galβ1–4Glc     
G44      Neu5Ac8Meα2–3Galβ1–3GlcNAcβ1–3Galβ1–4Glc     
G45      Neu5Gcα2–3Galβ1–4(Fucα1–3)GlcNAcβ1–3Galβ1–4Glc     
G46      Kdnα2–3Galβ1–4(Fucα1–3)GlcNAcβ1–3Galβ1–4Glc     
G47      Galα1–4Galβ1–4Glc     
136 
G48      Galα1–3Galβ1–4Glc     
G49      GalNAcβ1–3Galα1–4Galβ1–4Glc     
G50      GalNAcβ1–3Galα1–3Galβ1–4Glc     
G51      Galβ1–3GalNAcβ1–3Galα1–4Galβ1–4Glc     
G52      Galβ1–3GalNAcβ1–3Galα1–3Galβ1–4Glc     
G53      Fucα1-­2Galβ1-­3GalNAcβ1-­3Galα1-­4Galβ1-­4Glc     
G54      Neu5Gcα2–3Galβ1–3GalNAcβ1–3Galα1–4Galβ1–4Glc     
G55      Kdnα2–3Galβ1–3GalNAcβ1–3Galα1–4Galβ1–4Glc     
G56      Neu5Acα2–3Galβ1–3GalNAcβ1–3Galα1–3Galβ1–4Glc     
G57      Neu5Gcα2–3Galβ1–3GalNAcβ1–3Galα1–3Galβ1–4Glc     
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Abstract
O-GlcNAcase (OGA) is the only enzyme responsible for removing N-acetyl glucosamine (GlcNAc)
attached to serine and threonine residues on proteins. This enzyme plays a key role in O-GlcNAc
metabolism. However, the structural features of the sugar moiety recognized by human OGA (hOGA)
remain unclear. In this study, a set of glycopeptides with modifications on the GlcNAc residue, were
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